


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**BOX PCT/DO-EO**

Commissioner for Patents  
Washington, D.C. 20231

"Express Mail" mailing label number **EL 823 518 515 US**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and addressed to: Commissioner of Patents, Washington, DC 20231, on March 14 2002.

  
Susan C. Sheehan

**NATIONAL STAGE APPLICATION TRANSMITTAL LETTER**  
**APPLICATION FILING UNDER 35 U.S.C. § 371**

Transmitted herewith for filing is the patent application of:

<b>Inventor(s)/Applicant(s):</b>	<b>Thonnard, Joelle</b>
<b>International Application No.:</b>	<b>EP00/09034</b>
<b>International Published Appln. No.:</b>	<b>WO 01/19862</b>
<b>International Filing Date:</b>	<b>14 September 2000</b>
<b>Priority Filing Date:</b>	<b>14 September 1999, 25 September 1999</b>
<b>Thirty Month Date:</b>	<b>14 March 2002</b>
<b>Title:</b>	<b>"Novel Compounds"</b>

1. **THIS NEW APPLICATION IS A NATIONAL STAGE APPLICATION UNDER PCT, CHAPTER II WITH A REQUEST FOR EXAMINATION WITHOUT DELAY TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US).**

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. § 371;
- ☐ This is a **SECOND** or subsequent submission of items concerning a filing under 35 U.S.C. § 371.

2. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

3. A proper Demand for International Preliminary Examination was made by the 19<sup>TH</sup> month from the earliest claimed priority date.

4. Enclosed items are required for filing under 37 CFR § 1.53(b) and § 1.494(b) or § 1.495(b):

- ☒ One copy of International Publication **WO 01/19862**
- (a) ☒ is transmitted herewith (**required only if not transmitted by the International Bureau**)
- (b) ☒ has been transmitted by the International Bureau
- (c) ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)

#### Fees

☒ The basic national fee set forth in 37 CFR § 1.482 - International Preliminary Examination Fee not paid to USPTO but International Search Report prepared by the EPO or JPO - **\$860.00**

- ☒ Claims in Excess of 20 (3 @ \$18.00)
- ☐ Independent Claims in Excess of 3 (0 @ \$80.00)

5. Further enclosed are:

- ☒ One copy of International Preliminary Examination Report.
- ☒ One copy of International Search Report - (without references).
- ☐ One copy of Written Opinion.
- ☐ One copy of PCT Request as filed.
- ☐ One copy of Chapter II Demand as filed.

6. **Information Disclosure Statement:**

• The Examiner is requested to consider carefully the complete text of the documents submitted herewith in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the documents do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

- It is requested that the listed documents be included in the "References Cited" portion of any patent issuing from this application.

• Under 37 CFR 1.97(i), Applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office, however, under Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.

• Applicants make of record the enclosed documents, which include those documents identified in the International Search Report or in the International Preliminary Examination Report. These documents are listed on the enclosed Forms PTO/SB/08A and PTO/SB/08B.

7. ☐ A translation of the International Application into English (35 U.S.C. § 371(c)(2))

8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3))

9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3))

10. Still additional papers enclosed:

- ☐ Assignment with Assignment Recordation Form Cover Sheet  
☐ Verification Statement Claiming Small Entity Status  
☐ Declaration or oath is enclosed executed by the inventor  
☒ Return Acknowledgment Postcard

11. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

A. Enclosed are:

- (a) ☐ Computer Readable Copy of the Sequence Listing  
(b) ☒ Paper Copy (identical to Computer Readable Copy) of the Sequence Listing

B. ☐ Enclosed is a paper copy of the Sequence Listing. This paper copy and a Computer Readable Form thereof are identical with the Computer Readable Form in another application of the Applicant which is fully identified as follows:

U.S. Application No.: @@

Filed: @@

Attorney Docket No.: @@

which is believed to comply with the rules set forth in 37 CFR § 1.821 et. seq. Applicants requests pursuant to 37 CFR § 1.821(e) that this Computer Readable Form be used in the present application. **Please TRANSFER the sequence listing from the parent to this application.**

C. ☐ Statement under 37 CFR § 1.821(f): **The information recorded in computer readable form is identical to the written Sequence Listing.**

D. ☐ Statement under 37 CFR § 1.821(g) (required when Sequence Listing not submitted at the time of filing under 35 U.S.C. § 111(a)) or 37 CFR § 1.821(f) (required when Sequence Listing not submitted at the time of filing under the Patent Cooperation Treaty): **The submission of the Sequence Listing includes no new matter.**

E. ☒ Amendment: Please enter the Sequence Listing into the application.

12. **Preliminary Amendment**

Prior to calculation of fees, kindly enter:

- ☒ Preliminary Amendment submitted herewith  
☐ do not enter Preliminary Amendment


13. Fee payment being made at this time is enclosed:

* Basic filing fee (\$860.00)	860 00
* Claims in Excess of 20	
* (3 @ \$18.00)	
Independent Claims in Excess of 3	.00
(0 @ \$80.00)	
* Total Fees enclosed:	\$

14. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 50-0258. This letter is filed in duplicate for accounting purposes.

Respectfully submitted,

Date: March 14, 2002

  
Arthur E. Jackson  
Registration No. 34,354  
Attorney for Applicant

DECHERT  
4000 Bell Atlantic Tower  
1717 Arch Street  
Philadelphia, PA 19103-2793  
(609) 620-3254

129432 1 07



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3/8

Applicant: Thonnard, et al.

Docket No.: BM45414

Serial No.: Unknown

Filed: Herewith

For: Novel Compounds

Group Art Unit No.: Unknown

Examiner: Unknown

**PRELIMINARY AMENDMENT**

Sir:

Applicant respectfully requests that this Preliminary Amendment be entered in this case before the calculation of fees and before examination of the subject application.

**In the Specification:**

On page 1, please insert as the first paragraph of this application (after the title):

--This application is a National Phase Application of WO 01/19862, and claims priority of GB 9921694.7, filed 14 September 1999, GB 9921693 9; filed 14 September 1999, and GB 9922829.8; filed 25 September 1999.--

**In the Claims:**

Please delete the claims of the application as filed in the PCT and substitute therefor:

27. An isolated polypeptide comprising a member selected from the group consisting of
- (a) an amino acid sequence matching SEQ ID NO:2 or SEQ ID NO:4 or SEQ ID NO:6 and
  - (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids that matches an aligned contiguous segment of SEQ ID NO:2 or SEQ ID NO:4, or SEQ ID NO:6,

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T<sub>H</sub>-cell immune response to a polypeptide having the sequence of SEQ ID NO:2 or SEQ ID NO:4 or SEQ ID NO:6.

28. An isolated polynucleotide encoding a polypeptide of Claim 27 or the full complement to the isolated polynucleotide.

29. The isolated polypeptide of claim 27, wherein the polypeptide is according to (a).

30. An isolated polynucleotide encoding a polypeptide of Claim 29 or the full complement to the isolated polynucleotide.

31. A process for expressing the polynucleotide of Claim 30 comprising transforming a host cell with an expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.

32. The isolated polypeptide of claim 27, wherein the polypeptide is according to (b).

33. An isolated polynucleotide encoding a polypeptide of Claim 32 or the full complement to the isolated polynucleotide.

34. The isolated polypeptide of claim 27, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.

35. The isolated polypeptide of claim 27, wherein the isolated polypeptide consists of SEQ ID NO:2 or SEQ ID NO:4 or SEQ ID NO:6.

36. An isolated polynucleotide encoding the polypeptide of Claim 35 or the full complement to the isolated polynucleotide.

37. A process for expressing the polynucleotide of Claim 36 comprising transforming a host cell with an expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.

38. A fusion protein comprising the isolated polypeptide of Claim 21.

39. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO:5.

40. An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence hybridizes to the full complement of SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO:5 minus the complement of any stop codon, wherein the hybridization conditions include

incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing in 0.1x SSC at 65°C; and, wherein the polynucleotide sequence is identical to SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO: 5 minus any terminal stop codon, except that, over the entire length corresponding to SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO: 5 minus any terminal stop codon,  $n_n$  nucleotides are substituted, inserted or deleted, wherein  $n_n$  satisfies the following expression

$$n_n \leq x_n - (x_n \bullet y)$$

wherein  $x_n$  is the total number of nucleotides in SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO:5 minus any terminal stop codon,  $y$  is at least 0.95, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer before subtracting the product from  $x_n$ ; and wherein the polynucleotide sequence detects *Moraxella catarrhalis*.

41. An expression vector comprising the isolated polynucleotide of Claim 28
42. A host cell transformed with the expression vector of Claim 41.
43. A vaccine comprising the polypeptide of Claim 27 and a pharmaceutically acceptable carrier.
44. The vaccine of Claim 43, wherein the vaccine comprises at least one other *Moraxella catarrhalis* antigen.
45. An antibody immunospecific for the polypeptide or immunogenic fragment of Claim 27.
46. A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 27.
47. A method of diagnosing a *Moraxella catarrhalis* infection, comprising identifying a polypeptide of Claim 27, or an antibody that is immunospecific for the polypeptide, present within a biological sample from an animal suspected of having such an infection.

Support for the new claims is either apparent, or is as described in the text below.

Support for the hybridization conditions may be found, for example, at page 14, last paragraph.

Support for the recitation of sequence relatedness such as in claim 40 may be found in the specification, for example, at pages 46-50.

Closing Remarks

Allowance of the pending claims is respectfully requested.

Respectfully submitted,



Arthur E. Jackson  
Registration No. 34,354  
Allen Bloom  
Registration No. 29,135  
Attorneys for Applicants

DECHERT  
Princeton Pike Corporate Center  
P.O. Box 5218  
Princeton, New Jersey 08543-5218  
Allen Bloom (609) 620-3214  
Arthur E. Jackson (609) 620-3254  
Fax: (609) 620-3259  
Attn: Allen Bloom, Esq.

## SEQUENCE LISTING

<110> Joelle Thonnard

## <120> Novel Compounds

<130> BM45414

<150> 9921694.7

<151> 1999-09-14

<150> 9921693.9

<151> 1999-09-14

<150> 9922829.8

<151> 1999-09-25

<160> 6

<170> FastSEQ for Windows Version 4.0

 $\langle 210 \rangle$  1

<211> 1035

<212> DNA

<213> Moraxella catarrhalis

 $\langle 400 \rangle$  1

atgaaagcac	aatttacaac	cctaaaagtc	atcggcggac	tatttgtagg	tggcatgatg	60
ctaaatgcac	atgcagcacc	tgaattatat	ggttacgcaa	atcttgtcgt	ttctgctaata	120
cataaaaaaa	caaccaacaa	gacaaccaat	gtcagtagat	caacaacaga	ccgcccctat	180
ctgtatagca	gcggatcacg	cattggcctt	agagggtctg	aaaagttaaa	tgatgattat	240
gaggttttgt	acaagttgga	gtaccgtcta	gaaaatgatg	gtgattttacg	caatgaaaaa	300
atcaagcagc	cagatggtac	tgaaaagact	gttgctaaaa	cacgcaattt	tgaggctcgt	360
gattcatgga	ttggcgtgaa	gcataaaaaa	tatggtagca	tcaaggcgagg	tcgtatgttg	420
tctttggatc	catatgtgcg	ttatactgcc	tattttgcgt	caggcgtaga	tgggggtgcgt	480
accaataata	ccattgcata	cgaatcacca	aaaatcaaa	atgttagttt	tcaggcgatg	540
tacatcttag	atgaaaataa	agagacagat	accattgatc	gtgatgggta	ttcattgctt	600
gtcaagaaaa	acacagatac	atataatggt	ggtgcagctt	atgcctattt	tggtaaagca	660
aaaacctctt	atggcaagat	taactatact	gcgcgtgtga	caggtaaatta	taaaattaat	720
gaggattata	aagtaggtgg	tatctatcag	catgtcggct	atgccaatga	cgacagtgcc	780
aaaaataata	cagaacaagc	tgttggcgtg	gctttgcagc	attttaaaga	caaattggact	840
cataccgcac	acatgaatct	tgtgaataat	cctagtggga	aaaaggcgca	tggggttgag	900
ctgatcggag	caattgaccg	tgatatttct	aaaaatgtct	ctgcagcgat	ggatatcacc	960
tatggtaact	ttaactacgc	aacagaaaaa	gaatcttaca	tcaaccacaac	tatctatgcg	1020
actgtatat	tttaa					1035

<210> 2

<211> 344

<212> PRT

<213> Moraxella catarrhalis

<400> 2



ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED

<210> 4

<211> 678

&lt;212&gt; PRT

<213> Moraxella catarrhalis

<400> 4

Met	Arg	Phe	Ile	Pro	Phe	Ala	Val	Thr	Leu	Leu	Ser	Phe	Thr	Gly	Ser
1				5					10					15	
Ser	Ile	Phe	Ser	Val	Ala	Lys	Ala	Gln	Ile	Ala	Pro	Asp	Pro	Thr	Lys
			20					25					30		
Ala	Asn	Leu	Ser	Ala	Ile	Thr	Asp	Asp	Arg	Arg	Gln	Ala	Ala	Leu	Ala
		35					40					45			
His	Leu	Ala	Arg	Gln	Asp	Leu	Ala	Ala	Thr	Asp	Asp	Asp	Met	Gly	Val
	50					55					60				
Asp	Ile	Asn	Gln	Thr	Asn	Ile	Asn	Gln	Pro	Asn	Trp	Gln	Asp	Asp	Lys
65					70						75				80
Asn	Gly	Asp	Ser	Cys	Phe	Leu	Val	Asp	Glu	Ile	Asp	Phe	Val	Ile	Glu
			85						90					95	
Gly	Gly	Glu	Asp	Lys	His	Ile	Leu	Gly	Met	Thr	Pro	Ser	Asn	Leu	Arg
			100					105					110		
Ser	Leu	Leu	Ser	Pro	Leu	Leu	Asp	Arg	Thr	Lys	Pro	Thr	Tyr	Ala	Leu
		115					120					125			



Asn	His	Cys	Ile	Asn	Asn	His	Asn	Leu	Ser	Leu	Ile	Val	Asp	Ile	Ala
130						135					140				
His	Asn	Glu	Leu	Leu	Lys	Arg	Gly	Tyr	Leu	Thr	Ser	Ser	Ile	Ser	Ile
145					150					155					160
Glu	Glu	Gln	Asp	Leu	Ser	Thr	Lys	Lys	Leu	Thr	Leu	Thr	Val	His	Ala
				165					170					175	
Gly	Lys	Val	Lys	Lys	Val	Ile	Leu	Ala	Asp	Ala	Ser	Lys	Thr	Pro	Thr
			180					185					190		
Tyr	Val	Lys	Ala	Ala	Ile	Pro	Leu	Lys	Phe	Asn	Gln	Ala	Phe	Arg	Leu
		195					200					205			
Ser	Tyr	Leu	Glu	Gln	Gly	Leu	Asp	Asn	Leu	Lys	Arg	Ile	Asp	Pro	Thr
	210				215						220				
Ala	Thr	Val	Gln	Ile	Ile	Pro	Ser	Ser	Ser	Ser	Asn	Val	Ala	Asn	Asp
225				230						235					240
Ile	Asp	Ile	Asn	Thr	Thr	Asn	Leu	Gly	Phe	Ser	Asp	Leu	Leu	Ile	Arg
				245					250					255	
Met	Asp	Arg	Ser	Gln	Ser	Ala	Val	Phe	Gly	Ile	Asn	Ile	Asp	Asn	Ser
			260					265				270			
Leu	Ser	Lys	Asp	Tyr	Gly	Asn	Tyr	Leu	Ile	Ser	Ala	Asn	Val	Arg	Ala
		275					280					285			
Asn	Asn	Leu	Met	His	Leu	Asn	Asp	Glu	Trp	Asn	Leu	Ser	Ala	Asn	Tyr
						295					300				
Pro	Leu	Ala	Arg	Leu	Ile	Asp	Ala	Ala	Gln	Asn	Asp	Leu	Gly	Val	Gln
305				310						315					320
Val	Gly	Lys	Asp	Arg	Gln	Val	Asn	Tyr	His	Ala	Ser	Leu	Thr	Ile	Pro
				325					330					335	
Tyr	Gly	Leu	Tyr	Lys	Phe	Ser	Ala	Thr	His	Ser	His	His	Gln	Tyr	Gln
			340					345					350		
Gln	Phe	Leu	Glu	Gly	Leu	His	Ala	Pro	Leu	Thr	Tyr	His	Gly	Thr	Ser
		355					360					365			
Lys	Thr	Ser	Ser	Ile	Gly	Leu	Ser	Arg	Leu	Leu	His	Arg	Asp	Gly	Asn
	370				375						380				
Gln	Lys	Thr	Glu	Gly	Tyr	Ile	Lys	Val	Asn	His	Lys	Arg	Ser	Ser	Asn
385				390						395					400
Tyr	Ile	Asp	Asp	Val	Asn	Leu	Glu	Val	Gln	Asn	Arg	Arg	Thr	Thr	Gly
				405					410					415	
Tyr	Asn	Ile	Gly	Ile	Thr	His	Gln	His	His	Leu	His	Gln	Gly	Gly	Tyr
			420					425				430			
Leu	Tyr	Ala	Asn	Leu	Asp	Tyr	Lys	Gln	Gly	Thr	Gly	Ala	Leu	Lys	Ala
		435					440					445			
Lys	Pro	Ala	Pro	Glu	Glu	His	Ile	Tyr	Asp	Ala	Phe	Gly	Arg	Gln	Leu
		450				455					460				
Pro	Ser	Glu	Gly	Phe	Ala	Lys	Ala	Pro	Ile	Trp	Ser	Leu	Tyr	Thr	Ser
465				470						475					480

<400> 6

Met Lys Met Pro Tyr Phe Leu Leu Leu Gly Leu Leu Leu Val Gln Gln  
1 5 10 15  
Ala Asp Ala Asp Tyr Ser Leu Leu Asp Ala Gln Lys Gln Leu Met Ser  
20 25 30  
Ser Ser Pro Ala Ile Gln Ala Ser His Ala Leu Tyr Gln Ala Asp Val  
35 40 45  
Leu Gln Ala Glu Ser Leu Gln Lys Leu His Tyr Pro Arg Ile Ser Leu  
50 55 60  
Asn Ala His Ala Phe Val Leu Gln Gln Asn Ser Ser Ile Pro Leu Asp  
65 70 75 80  
His Ile Lys Glu Gln Thr Ala Gln His Ile Asn Thr His Phe Asp His  
85 90 95  
Arg Phe Gly Ser Ala Pro Asp Gly Leu Leu Asp Ala Leu His Asn Ser  
100 105 110  
Thr Gln Thr Ala Leu Asp Arg Leu Pro Asp His Gln Asp Val Lys Leu  
115 120 125  
Arg His Asp Gly Ile Thr Pro Asn Ile Thr Ala Thr Ile Pro Ile Tyr  
130 135 140  
Thr Gly Gly Leu Ile Ser Ser Thr Lys Asn Ile Ala Asn Leu Gln Ala  
145 150 155 160  
Gln Arg Gly Lys Phe Gly Leu Gln Glu Arg Ile Ser Leu Ala Lys Leu  
165 170 175  
Asn Leu Ile Arg His Tyr Phe Asn Val Gln Leu Gln Lys Gln Leu Thr  
180 185 190  
Asp Thr Gln Gln Asn Met Leu Ser Ala Met Gln Leu His Val Asp Asn  
195 200 205  
Ala Tyr Lys Leu Glu Gln Gln Gly Phe Ile Ser Arg Gly Gln Arg Met  
210 215 220  
Gln Phe Glu Val Ala Arg Asn Gln Val Gln Arg Leu Tyr Gln Ser Thr  
225 230 235 240  
Gln Asn Gln His Gln Asn Ser Ile Tyr Glu Leu Ala Val Leu Leu Gly  
245 250 255  
Leu Pro His Ile Glu Pro Leu Ser Thr Pro Leu Phe Ile Asn Thr Gln  
260 265 270  
His Arg Pro Asn Trp Gln Ala Leu Leu Lys Asp Ser Gln Asn Thr Pro  
275 280 285  
Leu Asn Gln Lys Leu Lys Thr Asp Ile Leu Leu Ala Asp Glu Asn Ile  
290 295 300  
Ala Leu Arg Gln Ser Thr Lys Lys Pro Lys Ile Ala Ala Val Ala Arg  
305 310 315 320  
Tyr Thr Leu Asp Asp Lys Pro Asp Trp Phe Ala Gly Val Ala Val Ser  
325 330 335  
Tyr Asn Leu Phe Leu Gly Ile Asp Arg Asp Lys Gln Ile Gly Ala Ala  
340 345 350  
His Leu Gln Lys Gln Ala Ala Gln Leu Gly His Glu Gln Val Asn Glu  
355 360 365  
His Ile Thr Thr Thr Met His Thr Ala Tyr Gly Glu Met Val Leu Ala  
370 375 380  
Gln Lys Thr His Ala Leu Leu Gln Gln Asn Arg Gln Ala Ala Lys Glu  
385 390 395 400  
Asn Leu Arg Ile Gln Thr Leu Ser Phe Gln Glu Gly Phe Gly Thr Val  
405 410 415  
Ala Gly Val Val Asp Ala Gln Ser Ala Leu Ser Gln Ile Asp Ser Glu  
420 425 430

7-

2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number  
**WO 01/19862 A2**

- (51) International Patent Classification<sup>7</sup>: **C07K 14/22**, 16/12, C12N 1/21, 15/31, A61K 38/16, 39/40, G01N 33/569
- (74) Agent: **PRIVETT, Kathryn, Louise**, SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).
- (21) International Application Number: PCT/EP00/09034
- (22) International Filing Date:  
14 September 2000 (14.09.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
9921694.7 14 September 1999 (14.09.1999) GB  
9921693.9 14 September 1999 (14.09.1999) GB  
9922829.8 25 September 1999 (25.09.1999) GB
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **SMITHKLINE BEECHAM BIOLOGICALS S.A.** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).
- Published:  
— Without international search report and to be republished upon receipt of that report
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **THONNARD, Joelle** [BE/BE], SmithKline Beecham Biologicals s.a., Rue de L'Institut 89, B-1330 Rixensart (BE).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

(54) Title: NOVEL COMPOUNDS

(57) Abstract: The invention provides BASB129, BASB130 and BASB131 polypeptides and polynucleotides encoding BASB129, BASB130 and BASB131 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

WO 01/19862 A2

## Novel Compounds

### FIELD OF THE INVENTION

This invention relates to polynucleotides, (herein referred to as "BASB129, BASB130 or BASB131 polynucleotide(s)"), polypeptides encoded by them (referred to herein as "BASB129, BASB130 or BASB131" or "BASB129, BASB130 or BASB131 polypeptide(s)"), recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including vaccines against bacterial infections. In a further aspect, the invention relates to diagnostic assays for detecting infection of certain pathogens.

### BACKGROUND OF THE INVENTION

*Moraxella catarrhalis* (also named *Branhamella catarrhalis*) is a Gram negative bacteria frequently isolated from the human upper respiratory tract. It is responsible for several pathologies the main ones being otitis media in infants and children, and pneumonia in elderlies. It is also responsible of sinusitis, nosocomial infections and less frequently of invasive diseases.

Otitis media is an important childhood disease both by the number of cases and its potential sequelae. More than 3.5 millions cases are recorded every year in the United States, and it is estimated that 80 % of the children have experienced at least one episode of otitis before reaching the age of 3 (Klein, JO (1994) Clin.Inf.Dis 19:823). Left untreated, or becoming chronic, this disease may lead to hearing losses that could be temporary (in the case of fluid accumulation in the middle ear) or permanent (if the auditive nerve is damaged). In infants, such hearing losses may be responsible for a delayed speech learning.

Three bacterial species are primarily isolated from the middle ear of children with otitis media: *Streptococcus pneumoniae*, non typeable *Haemophilus influenza* (NTHi) and *M. catarrhalis*. They are present in 60 to 90 % of the cases. A review of recent studies shows

that *S. pneumoniae* and NTHi represent both about 30 %, and *M. catarrhalis* about 15 % of the otitis media cases (Murphy, TF (1996) Microbiol.Rev. 60:267). Other bacteria could be isolated from the middle ear (*H. influenza* type B, *S. pyogenes* etc) but at a much lower frequency (2 % of the cases or less).

Epidemiological data indicate that, for the pathogens found in the middle ear, the colonization of the upper respiratory tract is an absolute prerequisite for the development of an otitis; other are however also required to lead to the disease (Dickinson, DP et al. (1988) J. Infect.Dis. 158:205, Faden, HL et al. (1991) Ann.Otorhinol.Laryngol. 100:612). These are important to trigger the migration of the bacteria into the middle ear via the Eustachian tubes, followed by the initiation of an inflammatory process. These factors are unknown todate. It has been postulated that a transient anomaly of the immune system following a viral infection, for example, could cause an inability to control the colonization of the respiratory tract (Faden, HL et al (1994) J. Infect.Dis. 169:1312). An alternative explanation is that the exposure to environmental factors allow a more important colonization of some children, who subsequently become susceptible to the development of otitis media because of the sustained presence of middle ear pathogens (Murphy, TF (1996) Microbiol.Rev. 60:267).

The immune response to *M. catarrhalis* is poorly characterized. The analysis of strains isolated sequentially from the nasopharynx of babies followed from 0 to 2 years of age, indicates that they get and eliminate frequently new strains. This indicates that an efficacious immune response against this bacteria is mounted by the colonized children (Faden, HL et al (1994) J. Infect.Dis. 169:1312).

In most adults tested, bactericidal antibodies have been identified (Chapman, AJ et al. (1985) J. Infect.Dis. 151:878). Strains of *M. catarrhalis* present variations in their capacity to resist serum bactericidal activity: in general, isolates from diseased individuals are more resistant than those who are simply colonized (Hol, C et al. (1993) Lancet 341:1281, Jordan,

KL et al. (1990) Am.J.Med. 88 (suppl. 5A):28S). Serum resistance could therefore be considered as a virulence factor of the bacteria. An opsonizing activity has been observed in the sera of children recovering from otitis media.

The antigens targetted by these different immune responses in humans have not been identified, with the exception of OMP B1, a 84 kDa protein which expression is regulated by iron, and that is recognized by the sera of patients with pneumonia (Sethi, S, et al. (1995) Infect.Immun. 63:1516) , and of UspA1 and UspA2 (Chen D. et al.(1999), Infect.Immun. 67:1310).

A few other membrane proteins present on the surface of *M. catarrhalis* have been characterized using biochemical method, or for their potential implication in the induction of a protective immunity (for review, see Murphy, TF (1996) Microbiol.Rev. 60:267). In a mouse pneumonia model, the presence of antibodies raised against some of them (UspA, CopB) favors a faster clearance of the pulmonary infection. Another polypeptide (OMP CD) is highly conserved among *M. catarrhalis* strains, and presents homologies with a porin of *Pseudomonas aeruginosa*, which has been demonstrated efficacious against this bacterium in animal models.

The frequency of *Moraxella catarrhalis* infections has risen dramatically in the past few decades. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate *Moraxella catarrhalis* strains that are resistant to some or all of the standard antibiotics. This phenomenon has created an unmet medical need and demand for new anti-microbial agents, vaccines, drug screening methods, and diagnostic tests for this organism.

## SUMMARY OF THE INVENTION



The present invention relates to BASB1298, BASB130 and BASB131, in particular BASB129, BASB130 and BASB131 polypeptides and BASB129, BASB130 and BASB131 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including prevention and treatment of microbial diseases, amongst others. In a further aspect, the invention relates to diagnostic assays for detecting diseases associated with microbial infections and conditions associated with such infections, such as assays for detecting expression or activity of BASB129, BASB130 and BASB131 polynucleotides or polypeptides.

Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.

#### **DESCRIPTION OF THE INVENTION**

The invention relates to BASB129, BASB130 and BASB131 polypeptides and polynucleotides as described in greater detail below.

In particular, the invention relates to polypeptides and polynucleotides of BASB129 of *Moraxella catarrhalis*, which is related by amino acid sequence homology to *Haemophilus influenzae* major outer membrane protein P2. The invention relates especially to BASB129 having the nucleotide and amino acid sequences set out in SEQ ID NO:1 and SEQ ID NO:2 respectively.

In particular, the invention also relates to polypeptides and polynucleotides of BASB130 of *Moraxella catarrhalis*, which is related by amino acid sequence homology to *Bordetella pertussis* hemolysin activator-like protein FhaC. The invention relates especially to BASB130 having the nucleotide and amino acid sequences set out in SEQ ID NO:3 and SEQ ID NO:4 respectively.

In particular, the invention also relates to polypeptides and polynucleotides of BASB131 of *Moraxella catarrhalis*, which is related by amino acid sequence homology to a lipase-

like protein of *Helicobacter pylori* and CyaE of *Bordetella pertusis*. The invention relates especially to BASB131 having the nucleotide and amino acid sequences set out in SEQ ID NO:5 and SEQ ID NO:6 respectively.

It is understood that sequences recited in the Sequence Listing below as "DNA" represent an exemplification of one embodiment of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including ribopolynucleotides.

### Polypeptides

In one aspect of the invention there are provided polypeptides of *Moraxella catarrhalis* referred to herein as "BASB129, BASB130 and BASB131" and "BASB129, BASB130 and BASB131 polypeptides" as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

The present invention further provides for:

- (a) an isolated polypeptide which comprises an amino acid sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% or exact identity, to that of SEQ ID NO:2, 4 or 6;
- (b) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:1, 3 or 5 over the entire length of SEQ ID NO:1, 3 or 5 respectively; or
- (c) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, even more preferably at least 97-99% or exact identity, to the amino acid sequence of SEQ ID NO:2, 4 or 6.

The BASB129, BASB130 and BASB131 polypeptides provided in SEQ ID NO:2, 4 or 6 are the BASB129, BASB130 and BASB131 polypeptides from *Moraxella catarrhalis* strain Mc2931 (ATCC 43617).

The invention also provides an immunogenic fragment of a BASB129, BASB130 and BASB131 polypeptide, that is, a contiguous portion of the BASB129, BASB130 and BASB131 polypeptide which has the same or substantially the same immunogenic activity as the polypeptide comprising the amino acid sequence of SEQ ID NO:2, 4 or 6; That is to say, the fragment (if necessary when coupled to a carrier) is capable of raising an immune response which recognises the BASB129, BASB130 and BASB131 polypeptide. Such an immunogenic fragment may include, for example, the BASB129, BASB130 and BASB131 polypeptide lacking an N-terminal leader sequence, and/or a transmembrane domain and/or a C-terminal anchor domain. In a preferred aspect the immunogenic fragment of BASB129, BASB130 and BASB131 according to the invention comprises substantially all of the extracellular domain of a polypeptide which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:2, 4 or 6 over the entire length of SEQ ID NO:2, 4 or 6 respectively.

A fragment is a polypeptide having an amino acid sequence that is entirely the same as part but not all of any amino acid sequence of any polypeptide of the invention. As with BASB129, BASB130 and BASB131 polypeptides, fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region in a single larger polypeptide.

Preferred fragments include, for example, truncation polypeptides having a portion of an amino acid sequence of SEQ ID NO:2, 4 or 6 or of variants thereof, such as a continuous series of residues that includes an amino- and/or carboxyl-terminal amino acid sequence. Degradation forms of the polypeptides of the invention produced by or in a host cell, are

also preferred. Further preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

Further preferred fragments include an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO:2, 4 or 6, or an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO:2, 4 or 6.

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these fragments may be employed as intermediates for producing the full-length polypeptides of the invention.

Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

The polypeptides, or immunogenic fragments, of the invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production. Furthermore, addition of exogenous polypeptide or lipid tail or polynucleotide sequences to increase the immunogenic potential of the final molecule is also considered.

In one aspect, the invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa.

Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

The proteins may be chemically conjugated, or expressed as recombinant fusion proteins allowing increased levels to be produced in an expression system as compared to non-fused protein. The fusion partner may assist in providing T helper epitopes (immunological fusion partner), preferably T helper epitopes recognised by humans, or assist in expressing the protein (expression enhancer) at higher yields than the native recombinant protein. Preferably the fusion partner will be both an immunological fusion partner and expression enhancing partner.

Fusion partners include protein D from *Haemophilus influenzae* and the non-structural protein from influenzae virus, NS1 (hemagglutinin). Another fusion partner is the protein known as LytA. Preferably the C terminal portion of the molecule is used. LytA is derived from *Streptococcus pneumoniae* which synthesize an N-acetyl-L-alanine amidase, amidase LytA, (coded by the lytA gene {Gene, 43 (1986) page 265-272}) an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The

C-terminal domain of the LytA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of E.coli C-LytA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LytA fragment at its amino terminus has been described {Biotechnology: 10, (1992) page 795-798}. It is possible to use the repeat portion of the LytA molecule found in the C terminal end starting at residue 178, for example residues 188 - 305.

The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr.

Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

It is most preferred that a polypeptide of the invention is derived from *Moraxella catarrhalis*, however, it may preferably be obtained from other organisms of the same taxonomic genus. A polypeptide of the invention may also be obtained, for example, from organisms of the same taxonomic family or order.

### Polynucleotides

It is an object of the invention to provide polynucleotides that encode BASB129, BASB130 and BASB131 polypeptides, particularly polynucleotides that encode the polypeptide herein designated BASB129, BASB130 and BASB131.

In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding BASB129, BASB130 and BASB131 polypeptides comprising a sequence set out in SEQ ID NO:1, 3 or 5 which includes a full length gene, or a variant thereof.

The BASB129, BASB130 and BASB131 polynucleotides provided in SEQ ID NO:1, 3 or 5 are the BASB129, BASB130 and BASB131 polynucleotides from *Moraxella catarrhalis* strain Mc2931 (ATCC 43617).

As a further aspect of the invention there are provided isolated nucleic acid molecules encoding and/or expressing BASB129, BASB130 and BASB131 polypeptides and polynucleotides, particularly *Moraxella catarrhalis* BASB129, BASB130 and BASB131 polypeptides and polynucleotides, including, for example, unprocessed RNAs, ribozyme RNAs, mRNAs, cDNAs, genomic DNAs, B- and Z-DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful polynucleotides and polypeptides, and variants thereof, and compositions comprising the same.

Another aspect of the invention relates to isolated polynucleotides, including at least one full length gene, that encodes a BASB129, BASB130 and BASB131 polypeptide having a deduced amino acid sequence of SEQ ID NO:2, 4 or 6 and polynucleotides closely related thereto and variants thereof.

In another particularly preferred embodiment of the invention there is a BASB129, BASB130 and BASB131 polypeptide from *Moraxella catarrhalis* comprising or consisting of an amino acid sequence of SEQ ID NO:2, 4 or 6 or a variant thereof.

Using the information provided herein, such as a polynucleotide sequence set out in SEQ ID NO:1, 3 or 5, a polynucleotide of the invention encoding BASB129, BASB130 and BASB131 polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Moraxella catarrhalis* Catlin cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as a polynucleotide sequence given in SEQ ID NO:1, 3 or 5, typically a library of clones of chromosomal DNA of *Moraxella catarrhalis* Catlin in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent hybridization conditions. By sequencing the individual clones thus identified by hybridization with sequencing primers designed from the original polypeptide or polynucleotide sequence it is then possible to extend the polynucleotide sequence in both directions to determine a full length gene sequence. Conveniently, such sequencing is performed, for example, using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Direct genomic DNA sequencing may also be performed to obtain a full length gene sequence. Illustrative of the invention, each polynucleotide set out in SEQ ID NO:1, 3 or 5 was discovered in a DNA library derived from *Moraxella catarrhalis*.

Moreover, each DNA sequence set out in SEQ ID NO:1, 3 or 5 contains an open reading frame encoding a protein having about the number of amino acid residues set forth in SEQ ID NO:2, 4 or 6 with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known to those skilled in the art.



The polynucleotide of SEQ ID NO:1, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 1033 of SEQ ID NO:1, encodes the polypeptide of SEQ ID NO:2.

The polynucleotide of SEQ ID NO:3, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 2035 of SEQ ID NO:3, encodes the polypeptide of SEQ ID NO:4.

The polynucleotide of SEQ ID NO:5, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 1408 of SEQ ID NO:5, encodes the polypeptide of SEQ ID NO:6.

In a further aspect, the present invention provides for an isolated polynucleotide comprising or consisting of:

- (a) a polynucleotide sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:1, 3 or 5 over the entire length of SEQ ID NO:1, 3 or 5 respectively; or
- (b) a polynucleotide sequence encoding a polypeptide which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, even more preferably at least 97-99% or 100% exact, to the amino acid sequence of SEQ ID NO:2, 4 or 6, over the entire length of SEQ ID NO:2, 4 or 6 respectively.

A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species other than *Moraxella catarrhalis*, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions (for example, using a temperature in the range of 45 – 65°C and an SDS concentration from 0.1 – 1%) with a labeled or detectable probe consisting of or comprising the sequence of SEQ ID NO:1, 3 or 5 or a fragment thereof; and isolating a full-length gene and/or genomic clones containing said polynucleotide sequence.

The invention provides a polynucleotide sequence identical over its entire length to a coding sequence (open reading frame) in SEQ ID NO:1, 3 or 5. Also provided by the invention is a coding sequence for a mature polypeptide or a fragment thereof, by itself as well as a coding sequence for a mature polypeptide or a fragment in reading frame with another coding sequence, such as a sequence encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence. The polynucleotide of the invention may also contain at least one non-coding sequence, including for example, but not limited to at least one non-coding 5' and 3' sequence, such as the transcribed but non-translated sequences, termination signals (such as rho-dependent and rho-independent termination signals), ribosome binding sites, Kozak sequences, sequences that stabilize mRNA, introns, and polyadenylation signals. The polynucleotide sequence may also comprise additional coding sequence encoding additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, *Proc. Natl. Acad. Sci., USA* 86: 821-824 (1989), or an HA peptide tag (Wilson *et al.*, *Cell* 37: 767 (1984), both of which may be useful in purifying polypeptide sequence fused to them. Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.

The nucleotide sequence encoding BASB129, BASB130 and BASB131 polypeptide of SEQ ID NO:2, 4 or 6 may be identical to the polypeptide encoding sequence contained in nucleotides 1 to 1033 of SEQ ID NO:1 or the polypeptide encoding sequence contained in nucleotides 1 to 2035 of SEQ ID NO:3 or the polypeptide encoding sequence contained in nucleotides 1 to 1408 of SEQ ID NO:5 respectively. Alternatively the nucleotide sequence encoding BASB129, BASB130 and BASB131 may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of

SEQ ID NO:2, 4 or 6.

The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the *Moraxella catarrhalis* BASB129, BASB130 and BASB131 having an amino acid sequence set out in SEQ ID NO:2, 4 or 6. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, polynucleotides interrupted by integrated phage, an integrated insertion sequence, an integrated vector sequence, an integrated transposon sequence, or due to RNA editing or genomic DNA reorganization) together with additional regions, that also may contain coding and/or non-coding sequences.

The invention further relates to variants of the polynucleotides described herein that encode variants of a polypeptide having a deduced amino acid sequence of SEQ ID NO:2, 4 or 6. Fragments of polynucleotides of the invention may be used, for example, to synthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding BASB129, BASB130 and BASB131 variants, that have the amino acid sequence of BASB129, BASB130 and BASB131 polypeptide of SEQ ID NO:2, 4 or 6 in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, modified, deleted and/or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of BASB129, BASB130 and BASB131 polypeptide.

Further preferred embodiments of the invention are polynucleotides that are at least 85% identical over their entire length to a polynucleotide encoding BASB129, BASB130 and BASB131 polypeptide having an amino acid sequence set out in SEQ ID NO:2, 4 or 6, and

polynucleotides that are complementary to such polynucleotides. Alternatively, most highly preferred are polynucleotides that comprise a region that is at least 90% identical over its entire length to a polynucleotide encoding BASB129, BASB130 and BASB131 polypeptide and polynucleotides complementary thereto. In this regard, polynucleotides at least 95% identical over their entire length to the same are particularly preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

Preferred embodiments are polynucleotides encoding polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA of SEQ ID NO:1, 3 or 5.

In accordance with certain preferred embodiments of this invention there are provided polynucleotides that hybridize, particularly under stringent conditions, to BASB129, BASB130 and BASB131 polynucleotide sequences, such as those polynucleotides in SEQ ID NO:1, 3 or 5.

The invention further relates to polynucleotides that hybridize to the polynucleotide sequences provided herein. In this regard, the invention especially relates to polynucleotides that hybridize under stringent conditions to the polynucleotides described herein. As herein used, the terms "stringent conditions" and "stringent hybridization conditions" mean hybridization occurring only if there is at least 95% and preferably at least 97% identity between the sequences. A specific example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C. Hybridization and wash conditions are well known and exemplified in Sambrook, *et al.*,

Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein. Solution hybridization may also be used with the polynucleotide sequences provided by the invention.

The invention also provides a polynucleotide consisting of or comprising a polynucleotide sequence obtained by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:1, 3 or 5 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:1, 3 or 5 or a fragment thereof; and isolating said polynucleotide sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers fully described elsewhere herein.

As discussed elsewhere herein regarding polynucleotide assays of the invention, for instance, the polynucleotides of the invention, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding BASB129, BASB130 and BASB131 and to isolate cDNA and genomic clones of other genes that have a high identity, particularly high sequence identity, to the BASB129, BASB130 and BASB131 gene. Such probes generally will comprise at least 15 nucleotide residues or base pairs. Preferably, such probes will have at least 30 nucleotide residues or base pairs and may have at least 50 nucleotide residues or base pairs. Particularly preferred probes will have at least 20 nucleotide residues or base pairs and will have less than 30 nucleotide residues or base pairs.

A coding region of a BASB129, BASB130 and BASB131 gene may be isolated by screening using a DNA sequence provided in SEQ ID NO:1, 3 or 5 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

There are several methods available and well known to those skilled in the art to obtain full-length DNAs, or extend short DNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman, *et al.*, *PNAS USA* 85: 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the DNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using "nested" primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the selected gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length DNA constructed either by joining the product directly to the existing DNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

The polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and materials for discovery of treatments of and diagnostics for diseases, particularly human diseases, as further discussed herein relating to polynucleotide assays.

The polynucleotides of the invention that are oligonucleotides derived from a sequence of SEQ ID NO:1, 3 or 5 may be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.

The invention also provides polynucleotides that encode a polypeptide that is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in vivo*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

For each and every polynucleotide of the invention there is provided a polynucleotide complementary to it. It is preferred that these complementary polynucleotides are fully complementary to each polynucleotide with which they are complementary.

A precursor protein, having a mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In addition to the standard A, G, C, T/U representations for nucleotides, the term "N" may also be used in describing certain polynucleotides of the invention. "N" means that any of the four DNA or RNA nucleotides may appear at such a designated position in the DNA or RNA sequence, except it is preferred that N is not a nucleic acid that when taken in combination with adjacent nucleotide positions, when read in the correct reading frame, would have the effect of generating a premature termination codon in such reading frame.

In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or

more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

In accordance with an aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization.

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff *et al.*, *Hum Mol Genet* (1992) 1: 363, Manthorpe *et al.*, *Hum. Gene Ther.* (1983) 4: 419), delivery of DNA complexed with specific protein carriers (Wu *et al.*, *J Biol Chem.* (1989) 264: 16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, *PNAS USA*, (1986) 83: 9551), encapsulation of DNA in various forms of liposomes (Kaneda *et al.*, *Science* (1989) 243: 375), particle bombardment (Tang *et al.*, *Nature* (1992) 356:152, Eisenbraun *et al.*, *DNA Cell Biol* (1993) 12: 791) and *in vivo* infection using cloned retroviral vectors (Seeger *et al.*, *PNAS USA* (1984) 81: 5849).

#### **Vectors, Host Cells, Expression Systems**

The invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the invention.

Recombinant polypeptides of the present invention may be prepared by processes well known in those skilled in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems that comprise a polynucleotide or polynucleotides of the present



invention, to host cells which are genetically engineered with such expression systems, and to the production of polypeptides of the invention by recombinant techniques.

For recombinant production of the polypeptides of the invention, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis, *et al.*, *BASIC METHODS IN MOLECULAR BIOLOGY*, (1986) and Sambrook, *et al.*, *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.

Representative examples of appropriate hosts include bacterial cells, such as cells of streptococci, staphylococci, enterococci, *E. coli*, streptomyces, cyanobacteria, *Bacillus subtilis*, *Neisseria meningitidis* and *Moraxella catarrhalis*; fungal cells, such as cells of a yeast, *Kluveromyces*, *Saccharomyces*, a basidiomycete, *Candida albicans* and *Aspergillus*; insect cells such as cells of *Drosophila* S2 and *Spodoptera* Sf9; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293, CV-1 and Bowes melanoma cells; and plant cells, such as cells of a gymnosperm or angiosperm.

A great variety of expression systems can be used to produce the polypeptides of the invention. Such vectors include, among others, chromosomal-, episomal- and virus-derived vectors, for example, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses, picornaviruses, retroviruses, and alphaviruses and vectors derived from combinations thereof, such as those derived from

plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, *MOLECULAR CLONING, A LABORATORY MANUAL*, (*supra*).

In recombinant expression systems in eukaryotes, for secretion of a translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, ion metal affinity chromatography (IMAC) is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and or purification.

The expression system may also be a recombinant live microorganism, such as a virus or bacterium. The gene of interest can be inserted into the genome of a live recombinant virus or bacterium. Inoculation and *in vivo* infection with this live vector will lead to *in vivo* expression of the antigen and induction of immune responses. Viruses and bacteria used for this purpose are for instance: poxviruses (e.g; vaccinia, fowlpox, canarypox), alphaviruses (Sindbis virus, Semliki Forest Virus, Venezuelan Equine Encephalitis

Virus), adenoviruses, adeno-associated virus, picornaviruses (poliovirus, rhinovirus), herpesviruses (varicella zoster virus, etc), Listeria, Salmonella, Shigella, BCG. These viruses and bacteria can be virulent, or attenuated in various ways in order to obtain live vaccines. Such live vaccines also form part of the invention.

#### **Diagnostic, Prognostic, Serotyping and Mutation Assays**

This invention is also related to the use of BASB129, BASB130 and BASB131 polynucleotides and polypeptides of the invention for use as diagnostic reagents. Detection of BASB129, BASB130 and BASB131 polynucleotides and/or polypeptides in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of disease, staging of disease or response of an infectious organism to drugs. Eukaryotes, particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism comprising the BASB129, BASB130 and BASB131 gene or protein, may be detected at the nucleic acid or amino acid level by a variety of well known techniques as well as by methods provided herein.

Polypeptides and polynucleotides for prognosis, diagnosis or other analysis may be obtained from a putatively infected and/or infected individual's bodily materials. Polynucleotides from any of these sources, particularly DNA or RNA, may be used directly for detection or may be amplified enzymatically by using PCR or any other amplification technique prior to analysis. RNA, particularly mRNA, cDNA and genomic DNA may also be used in the same ways. Using amplification, characterization of the species and strain of infectious or resident organism present in an individual, may be made by an analysis of the genotype of a selected polynucleotide of the organism. Deletions and insertions can be detected by a change in size of the amplified product in comparison to a genotype of a reference sequence selected from a related organism, preferably a different species of the same genus or a different strain of the same species. Point mutations can be identified by hybridizing amplified DNA to labeled BASB129, BASB130 and BASB131 polynucleotide sequences. Perfectly or significantly matched sequences can be distinguished from imperfectly or more

significantly mismatched duplexes by DNase or RNase digestion, for DNA or RNA respectively, or by detecting differences in melting temperatures or renaturation kinetics. Polynucleotide sequence differences may also be detected by alterations in the electrophoretic mobility of polynucleotide fragments in gels as compared to a reference sequence. This may be carried out with or without denaturing agents. Polynucleotide differences may also be detected by direct DNA or RNA sequencing. See, for example, Myers *et al.*, *Science*, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase, V1 and S1 protection assay or a chemical cleavage method. See, for example, Cotton *et al.*, *Proc. Natl. Acad. Sci., USA*, 85: 4397-4401 (1985).

In another embodiment, an array of oligonucleotide probes comprising BASB129, BASB130 and BASB131 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of, for example, genetic mutations, serotype, taxonomic classification or identification. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see, for example, Chee *et al.*, *Science*, 274: 610 (1996)).

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO:1, 3 or 5, or a fragment thereof;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2, 4 or 6 or a fragment thereof; or
- (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2, 4 or 6.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a Disease, among others.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of a polynucleotide of the invention, preferably SEQ ID NO:1, 3 or 5, which is associated with a disease or pathogenicity will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, a prognosis of a course of disease, a determination of a stage of disease, or a susceptibility to a disease, which results from under-expression, over-expression or altered expression of the polynucleotide. Organisms, particularly infectious organisms, carrying mutations in such polynucleotide may be detected at the polynucleotide level by a variety of techniques, such as those described elsewhere herein.

Cells from an organism carrying mutations or polymorphisms (allelic variations) in a polynucleotide and/or polypeptide of the invention may also be detected at the polynucleotide or polypeptide level by a variety of techniques, to allow for serotyping, for example. For example, RT-PCR can be used to detect mutations in the RNA. It is particularly preferred to use RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan. RNA, cDNA or genomic DNA may also be used for the same purpose, PCR. As an example, PCR primers complementary to a polynucleotide encoding BASB129, BASB130 and BASB131 polypeptide can be used to identify and analyze mutations.

The invention further provides primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. These primers may be used for, among other things, amplifying BASB129, BASB130 and BASB131 DNA and/or RNA isolated from a sample derived from an individual, such as a bodily material. The primers may be used to amplify a polynucleotide isolated from an infected individual, such that the polynucleotide may then

be subject to various techniques for elucidation of the polynucleotide sequence. In this way, mutations in the polynucleotide sequence may be detected and used to diagnose and/or prognose the infection or its stage or course, or to serotype and/or classify the infectious agent.

The invention further provides a process for diagnosing, disease, preferably bacterial infections, more preferably infections caused by *Moraxella catarrhalis*, comprising determining from a sample derived from an individual, such as a bodily material, an increased level of expression of polynucleotide having a sequence of SEQ ID NO:1, 3 or 5. Increased or decreased expression of a BASB129, BASB130 and BASB131 polynucleotide can be measured using any one of the methods well known in the art for the quantitation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting, spectrometry and other hybridization methods.

In addition, a diagnostic assay in accordance with the invention for detecting over-expression of BASB129, BASB130 and BASB131 polypeptide compared to normal control tissue samples may be used to detect the presence of an infection, for example. Assay techniques that can be used to determine levels of a BASB129, BASB130 and BASB131 polypeptide, in a sample derived from a host, such as a bodily material, are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis, antibody sandwich assays, antibody detection and ELISA assays.

The polynucleotides of the invention may be used as components of polynucleotide arrays, preferably high density arrays or grids. These high density arrays are particularly useful for diagnostic and prognostic purposes. For example, a set of spots each comprising a different gene, and further comprising a polynucleotide or polynucleotides of the invention, may be used for probing, such as using hybridization or nucleic acid amplification, using a probes obtained or derived from a bodily sample,

to determine the presence of a particular polynucleotide sequence or related sequence in an individual. Such a presence may indicate the presence of a pathogen, particularly *Moraxella catarrhalis*, and may be useful in diagnosing and/or prognosing disease or a course of disease. A grid comprising a number of variants of the polynucleotide sequence of SEQ ID NO:1, 3 or 5 are preferred. Also preferred is a comprising a number of variants of a polynucleotide sequence encoding the polypeptide sequence of SEQ ID NO:2, 4 or 6.

### Antibodies

The polypeptides and polynucleotides of the invention or variants thereof, or cells expressing the same can be used as immunogens to produce antibodies immunospecific for such polypeptides or polynucleotides respectively. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

In certain preferred embodiments of the invention there are provided antibodies against BASB129, BASB130 and BASB131 polypeptides or polynucleotides.

Antibodies generated against the polypeptides or polynucleotides of the invention can be obtained by administering the polypeptides and/or polynucleotides of the invention, or epitope-bearing fragments of either or both, analogues of either or both, or cells expressing either or both, to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique known in the art that provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, pg. 77-96 in *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc. (1985).

Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to polypeptides or polynucleotides of this invention. Also, transgenic mice, or other organisms or animals, such as other mammals, may be used to express humanized antibodies immunospecific to the polypeptides or polynucleotides of the invention.

Alternatively, phage display technology may be utilized to select antibody genes with binding activities towards a polypeptide of the invention either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-BASB129, --BASB130 and -BASB131 or from naive libraries (McCafferty, *et al.*, (1990), *Nature* 348, 552-554; Marks, *et al.*, (1992) *Biotechnology* 10, 779-783). The affinity of these antibodies can also be improved by, for example, chain shuffling (Clackson *et al.*, (1991) *Nature* 352: 628).

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides or polynucleotides of the invention to purify the polypeptides or polynucleotides by, for example, affinity chromatography.

Thus, among others, antibodies against BASB1029, BASB130 and BASB131-polypeptide or BASB129, BASB130 and BASB131-polynucleotide may be employed to treat infections, particularly bacterial infections.

Polypeptide variants include antigenically, epitopically or immunologically equivalent variants form a particular aspect of this invention.

Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized," where the complimentarity determining region or regions of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as



described in Jones *et al.* (1986), *Nature* 321, 522-525 or Tempest *et al.*, (1991) *Biotechnology* 9, 266-273.

#### **Antagonists and Agonists - Assays and Molecules**

Polypeptides and polynucleotides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, *e.g.*, Coligan *et al.*, *Current Protocols in Immunology* 1(2): Chapter 5 (1991).

The screening methods may simply measure the binding of a candidate compound to the polypeptide or polynucleotide, or to cells or membranes bearing the polypeptide or polynucleotide, or a fusion protein of the polypeptide by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide or polynucleotide, using detection systems appropriate to the cells comprising the polypeptide or polynucleotide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptide and/or constitutively expressed polypeptides and polynucleotides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide or polynucleotide, as the case may be. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide or polynucleotide of the present invention, to form a mixture, measuring BASB129, BASB130 and BASB131 polypeptide and/or polynucleotide activity in the mixture, and comparing the BASB129, BASB130 and BASB131

polypeptide and/or polynucleotide activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and BASB129, BASB130 and BASB131 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists of the polypeptide of the present invention, as well as of phylogenetically and and/or functionally related polypeptides (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies that bind to and/or interact with a polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and/or polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of BASB129, BASB130 and BASB131 polypeptides or polynucleotides, particularly those compounds that are bacteriostatic and/or bactericidal. The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising BASB129, BASB130 and BASB131 polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a BASB129, BASB130 and BASB131 agonist or antagonist. The ability of the candidate molecule to agonize or antagonize the BASB129, BASB130 and BASB131 polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously,

*i.e.*, without inducing the effects of BASB129, BASB130 and BASB131 polypeptide are most likely to be good antagonists. Molecules that bind well and, as the case may be, increase the rate of product production from substrate, increase signal transduction, or increase chemical channel activity are agonists. Detection of the rate or level of, as the case may be, production of product from substrate, signal transduction, or chemical channel activity may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colorimetric, labeled substrate converted into product, a reporter gene that is responsive to changes in BASB129, BASB130 and BASB131 polynucleotide or polypeptide activity, and binding assays known in the art.

Another example of an assay for BASB129, BASB130 and BASB131 agonists is a competitive assay that combines BASB129, BASB130 and BASB131 and a potential agonist with BASB129, BASB130 and BASB131-binding molecules, recombinant BASB129, BASB130 and BASB131 binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. BASB129, BASB130 and BASB131 can be labeled, such as by radioactivity or a colorimetric compound, such that the number of BASB129, BASB130 and BASB131 molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include, among others, small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide and/or polypeptide of the invention and thereby inhibit or extinguish its activity or expression. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing BASB129, BASB130 and BASB131-induced activities, thereby preventing the action or expression of BASB129, BASB130 and BASB131 polypeptides and/or polynucleotides by excluding BASB129, BASB130 and BASB131 polypeptides and/or polynucleotides from binding.

Potential antagonists include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, *J. Neurochem.* 56: 560 (1991); *OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION*, CRC Press, Boca Raton, FL (1988), for a description of these molecules). Preferred potential antagonists include compounds related to and variants of BASB129, BASB130 and BASB131.

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

Each of the polynucleotide sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs. Additionally, the polynucleotide sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno

or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The invention also provides the use of the polypeptide, polynucleotide, agonist or antagonist of the invention to interfere with the initial physical interaction between a pathogen or pathogens and a eukaryotic, preferably mammalian, host responsible for sequelae of infection. In particular, the molecules of the invention may be used: in the prevention of adhesion of bacteria, in particular gram positive and/or gram negative bacteria, to eukaryotic, preferably mammalian, extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block bacterial adhesion between eukaryotic, preferably mammalian, extracellular matrix proteins and bacterial BASB129, BASB130 and BASB131 proteins that mediate tissue damage and/or; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.

In accordance with yet another aspect of the invention, there are provided BASB129, BASB130 and BASB131 agonists and antagonists, preferably bacteristatic or bactericidal agonists and antagonists.

The antagonists and agonists of the invention may be employed, for instance, to prevent, inhibit and/or treat diseases.

In a further aspect, the present invention relates to mimotopes of the polypeptide of the invention. A mimotope is a peptide sequence, sufficiently similar to the native peptide (sequentially or structurally), which is capable of being recognised by antibodies which recognise the native peptide; or is capable of raising antibodies which recognise the native peptide when coupled to a suitable carrier.

Peptide mimotopes may be designed for a particular purpose by addition, deletion or substitution of elected amino acids. Thus, the peptides may be modified for the purposes of ease of conjugation to a protein carrier. For example, it may be desirable for some chemical conjugation methods to include a terminal cysteine. In addition it may be desirable for peptides conjugated to a protein carrier to include a hydrophobic terminus distal from the conjugated terminus of the peptide, such that the free unconjugated end of the peptide remains associated with the surface of the carrier protein. Thereby presenting the peptide in a conformation which most closely resembles that of the peptide as found in the context of the whole native molecule. For example, the peptides may be altered to have an N-terminal cysteine and a C-terminal hydrophobic amidated tail. Alternatively, the addition or substitution of a D-stereoisomer form of one or more of the amino acids may be performed to create a beneficial derivative, for example to enhance stability of the peptide.

Alternatively, peptide mimotopes may be identified using antibodies which are capable themselves of binding to the polypeptides of the present invention using techniques such as phage display technology (EP 0 552 267 B1). This technique, generates a large number of peptide sequences which mimic the structure of the native peptides and are, therefore, capable of binding to anti-native peptide antibodies, but may not necessarily themselves share significant sequence homology to the native polypeptide.

### Vaccines

Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal, preferably humans, which comprises inoculating the individual with BASB129, BASB130 and BASB131 polynucleotide and/or polypeptide, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bacterial infection and most particularly *Moraxella catarrhalis* infection. Also provided are methods whereby such immunological response slows bacterial replication. Yet another aspect of

the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector, sequence or ribozyme to direct expression of BASB129, BASB130 and BASB131 polynucleotide and/or polypeptide, or a fragment or a variant thereof, for expressing BASB129, BASB130 and BASB131 polynucleotide and/or polypeptide, or a fragment or a variant thereof *in vivo* in order to induce an immunological response, such as, to produce antibody and/ or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual, preferably a human, from disease, whether that disease is already established within the individual or not. One example of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a ribozyme, a modified nucleic acid, a DNA/RNA hybrid, a DNA-protein complex or an RNA-protein complex.

A further aspect of the invention relates to an immunological composition that when introduced into an individual, preferably a human, capable of having induced within it an immunological response, induces an immunological response in such individual to a BASB129, BASB130 and BASB131 polynucleotide and/or polypeptide encoded therefrom, wherein the composition comprises a recombinant BASB129, BASB130 and BASB131 polynucleotide and/or polypeptide encoded therefrom and/or comprises DNA and/or RNA which encodes and expresses an antigen of said BASB129, BASB130 and BASB131 polynucleotide, polypeptide encoded therefrom, or other polypeptide of the invention. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity and/or cellular immunity, such as cellular immunity arising from CTL or CD4+ T cells.

A BASB129, BASB130 and BASB131 polypeptide or a fragment thereof may be fused with co-protein or chemical moiety which may or may not by itself produce antibodies, but which is capable of stabilizing the first protein and producing a fused or modified protein which will have antigenic and/or immunogenic properties, and preferably

protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as lipoprotein D from *Haemophilus influenzae*, Glutathione-S-transferase (GST) or beta-galactosidase, or any other relatively large co-protein which solubilizes the protein and facilitates production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system of the organism receiving the protein. The co-protein may be attached to either the amino- or carboxy-terminus of the first protein.

In a vaccine composition according to the invention, a BASB129, BASB130 and BASB131 polypeptide and/or polynucleotide, or a fragment, or a mimotope, or a variant thereof may be present in a vector, such as the live recombinant vectors described above for example live bacterial vectors.

Also suitable are non-live vectors for the BASB129, BASB130 and BASB131 polypeptide, for example bacterial outer-membrane vesicles or "blebs". OM blebs are derived from the outer membrane of the two-layer membrane of Gram-negative bacteria and have been documented in many Gram-negative bacteria (Zhou, L *et al.* 1998. *FEMS Microbiol. Lett.* 163:223-228) including *C. trachomatis* and *C. psittaci*. A non-exhaustive list of bacterial pathogens reported to produce blebs also includes: *Bordetella pertussis*, *Borrelia burgdorferi*, *Brucella melitensis*, *Brucella ovis*, *Escherichia coli*, *Haemophilus influenza*, *Legionella pneumophila*, *Moraxella catarrhalis*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pseudomonas aeruginosa* and *Yersinia enterocolitica*.

Blebs have the advantage of providing outer-membrane proteins in their native conformation and are thus particularly useful for vaccines. Blebs can also be improved for vaccine use by engineering the bacterium so as to modify the expression of one or more molecules at the outer membrane. Thus for example the expression of a desired immunogenic protein at the outer membrane, such as the BASB129, BASB130 and BASB131 polypeptide, can be introduced or upregulated (e.g. by altering the promoter).



Instead or in addition, the expression of outer-membrane molecules which are either not relevant (e.g. unprotective antigens or immunodominant but variable proteins) or detrimental (e.g. toxic molecules such as LPS, or potential inducers of an autoimmune response) can be downregulated. These approaches are discussed in more detail below.

The non-coding flanking regions of the BASB129, BASB130 and BASB131 gene contain regulatory elements important in the expression of the gene. This regulation takes place both at the transcriptional and translational level. The sequence of these regions, either upstream or downstream of the open reading frame of the gene, can be obtained by DNA sequencing. This sequence information allows the determination of potential regulatory motifs such as the different promoter elements, terminator sequences, inducible sequence elements, repressors, elements responsible for phase variation, the shine-dalgarno sequence, regions with potential secondary structure involved in regulation, as well as other types of regulatory motifs or sequences. This sequence is a further aspect of the invention.

This sequence information allows the modulation of the natural expression of the BASB129, BASB130 and BASB131 gene. The upregulation of the gene expression may be accomplished by altering the promoter, the shine-dalgarno sequence, potential repressor or operator elements, or any other elements involved. Likewise, downregulation of expression can be achieved by similar types of modification. Alternatively, by changing phase variation sequences, the expression of the gene can be put under phase variation control, or it may be uncoupled from this regulation. In another approach, the expression of the gene can be put under the control of one or more inducible elements allowing regulated expression. Examples of such regulation include, but are not limited to, induction by temperature shift, addition of inductor substrates like selected carbohydrates or their derivatives, trace elements, vitamins, co-factors, metal ions, etc.

Such modifications as described above can be introduced by several different means. The modification of sequences involved in gene expression can be carried out *in vivo* by random mutagenesis followed by selection for the desired phenotype. Another approach consists in isolating the region of interest and modifying it by random mutagenesis, or site-directed replacement, insertion or deletion mutagenesis. The modified region can then be reintroduced into the bacterial genome by homologous recombination, and the effect on gene expression can be assessed. In another approach, the sequence knowledge of the region of interest can be used to replace or delete all or part of the natural regulatory sequences. In this case, the regulatory region targeted is isolated and modified so as to contain the regulatory elements from another gene, a combination of regulatory elements from different genes, a synthetic regulatory region, or any other regulatory region, or to delete selected parts of the wild-type regulatory sequences. These modified sequences can then be reintroduced into the bacterium via homologous recombination into the genome. A non-exhaustive list of preferred promoters that could be used for up-regulation of gene expression includes the promoters *porA*, *porB*, *lbpB*, *tbpB*, *p110*, *lst*, *hpuAB* from *N. meningitidis* or *N. gonorrhoeae*; *ompCD*, *copB*, *lbpB*, *ompE*, *UspA1*; *UspA2*; *TbpB* from *M. Catarrhalis*; *p1*, *p2*, *p4*, *p5*, *p6*, *lpD*, *tbpB*, *D15*, *Hia*, *Hmw1*, *Hmw2* from *H. influenzae*.

In one example, the expression of the gene can be modulated by exchanging its promoter with a stronger promoter (through isolating the upstream sequence of the gene, *in vitro* modification of this sequence, and reintroduction into the genome by homologous recombination). Upregulated expression can be obtained in both the bacterium as well as in the outer membrane vesicles shed (or made) from the bacterium.

In other examples, the described approaches can be used to generate recombinant bacterial strains with improved characteristics for vaccine applications. These can be, but are not limited to, attenuated strains, strains with increased expression of selected antigens, strains with knock-outs (or decreased expression) of genes interfering with the immune

response, strains with modulated expression of immunodominant proteins, strains with modulated shedding of outer-membrane vesicles.

Thus, also provided by the invention is a modified upstream region of the BASB129, BASB130 and BASB131 gene, which modified upstream region contains a heterologous regulatory element which alters the expression level of the BASB129, BASB130 and BASB131 protein located at the outer membrane. The upstream region according to this aspect of the invention includes the sequence upstream of the BASB129, BASB130 and BASB131 gene. The upstream region starts immediately upstream of the BASB129, BASB130 and BASB131 gene and continues usually to a position no more than about 1000 bp upstream of the gene from the ATG start codon. In the case of a gene located in a polycistronic sequence (operon) the upstream region can start immediately preceding the gene of interest, or preceding the first gene in the operon. Preferably, a modified upstream region according to this aspect of the invention contains a heterologous promotor at a position between 500 and 700 bp upstream of the ATG.

Thus, the invention provides a BASB129, BASB130 and BASB131 polypeptide, in a modified bacterial bleb. The invention further provides modified host cells capable of producing the non-live membrane-based bleb vectors. The invention further provides nucleic acid vectors comprising the BASB129, BASB130 and BASB131 gene having a modified upstream region containing a heterologous regulatory element.

Further provided by the invention are processes to prepare the host cells and bacterial blebs according to the invention.

Also provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides and/or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. *et al.* Science 273: 352 (1996).

Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof, which have been shown to encode non-variable regions of bacterial cell surface proteins, in polynucleotide constructs used in such genetic immunization experiments in animal models of infection with *Moraxella catarrhalis*. Such experiments will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value, derived from the requisite organ of the animal successfully resisting or clearing infection, for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly *Moraxella catarrhalis* infection, in mammals, particularly humans.

The invention also includes a vaccine formulation which comprises an immunogenic recombinant polypeptide and/or polynucleotide of the invention together with a suitable carrier, such as a pharmaceutically acceptable carrier. Since the polypeptides and polynucleotides may be broken down in the stomach, each is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostatic compounds and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.

The vaccine formulation of the invention may also include adjuvant systems for enhancing the immunogenicity of the formulation. Preferably the adjuvant system raises preferentially a TH1 type of response.

An immune response may be broadly distinguished into two extreme categories, being a humoral or cell mediated immune responses (traditionally characterised by antibody and cellular effector mechanisms of protection respectively). These categories of response have been termed TH1-type responses (cell-mediated response), and TH2-type immune responses (humoral response).

Extreme TH1-type immune responses may be characterised by the generation of antigen specific, haplotype restricted cytotoxic T lymphocytes, and natural killer cell responses. In mice TH1-type responses are often characterised by the generation of antibodies of the IgG2a subtype, whilst in the human these correspond to IgG1 type antibodies. TH2-type immune responses are characterised by the generation of a broad range of immunoglobulin isotypes including in mice IgG1, IgA, and IgM.

It can be considered that the driving force behind the development of these two types of immune responses are cytokines. High levels of TH1-type cytokines tend to favour the induction of cell mediated immune responses to the given antigen, whilst high levels of TH2-type cytokines tend to favour the induction of humoral immune responses to the antigen.

The distinction of TH1 and TH2-type immune responses is not absolute. In reality an individual will support an immune response which is described as being predominantly TH1 or predominantly TH2. However, it is often convenient to consider the families of cytokines in terms of that described in murine CD4 +ve T cell clones by Mosmann and Coffman (*Mosmann, T.R. and Coffman, R.L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology, 7, p145-173*). Traditionally, TH1-type responses are associated with the production of the INF- $\gamma$  and IL-2 cytokines by T-lymphocytes. Other cytokines often directly associated with the induction of TH1-type immune responses are not

produced by T-cells, such as IL-12. In contrast, TH2- type responses are associated with the secretion of IL-4, IL-5, IL-6 and IL-13.

It is known that certain vaccine adjuvants are particularly suited to the stimulation of either TH1 or TH2 - type cytokine responses. Traditionally the best indicators of the TH1:TH2 balance of the immune response after a vaccination or infection includes direct measurement of the production of TH1 or TH2 cytokines by T lymphocytes *in vitro* after restimulation with antigen, and/or the measurement of the IgG1:IgG2a ratio of antigen specific antibody responses.

Thus, a TH1-type adjuvant is one which preferentially stimulates isolated T-cell populations to produce high levels of TH1-type cytokines when re-stimulated with antigen *in vitro*, and promotes development of both CD8+ cytotoxic T lymphocytes and antigen specific immunoglobulin responses associated with TH1-type isotype.

Adjuvants which are capable of preferential stimulation of the TH1 cell response are described in International Patent Application No. WO 94/00153 and WO 95/17209.

3 De-O-acylated monophosphoryl lipid A (3D-MPL) is one such adjuvant. This is known from GB 2220211 (Ribi). Chemically it is a mixture of 3 De-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains and is manufactured by Ribi Immunochem, Montana. A preferred form of 3 De-O-acylated monophosphoryl lipid A is disclosed in European Patent 0 689 454 B1 (SmithKline Beecham Biologicals SA).

Preferably, the particles of 3D-MPL are small enough to be sterile filtered through a 0.22micron membrane (European Patent number 0 689 454).

3D-MPL will be present in the range of 10µg - 100µg preferably 25-50µg per dose wherein the antigen will typically be present in a range 2-50µg per dose.

Another preferred adjuvant comprises QS21, an Hplc purified non-toxic fraction derived from the bark of *Quillaja Saponaria* Molina. Optionally this may be admixed with 3 De-O-acylated monophosphoryl lipid A (3D-MPL), optionally together with an carrier.

The method of production of QS21 is disclosed in US patent No. 5,057,540.

Non-reactogenic adjuvant formulations containing QS21 have been described previously (WO 96/33739). Such formulations comprising QS21 and cholesterol have been shown to be successful TH1 stimulating adjuvants when formulated together with an antigen.

Further adjuvants which are preferential stimulators of TH1 cell response include immunomodulatory oligonucleotides, for example unmethylated CpG sequences as disclosed in WO 96/02555.

Combinations of different TH1 stimulating adjuvants, such as those mentioned hereinabove, are also contemplated as providing an adjuvant which is a preferential stimulator of TH1 cell response. For example, QS21 can be formulated together with 3D-MPL. The ratio of QS21 : 3D-MPL will typically be in the order of 1 : 10 to 10 : 1; preferably 1:5 to 5 : 1 and often substantially 1 : 1. The preferred range for optimal synergy is 2.5 : 1 to 1 : 1 3D-MPL: QS21.

Preferably a carrier is also present in the vaccine composition according to the invention. The carrier may be an oil in water emulsion, or an aluminium salt, such as aluminium phosphate or aluminium hydroxide.

A preferred oil-in-water emulsion comprises a metabolisable oil, such as squalene, alpha tocopherol and Tween 80. In a particularly preferred aspect the antigens in the vaccine composition according to the invention are combined with QS21 and 3D-MPL in such

an emulsion. Additionally the oil in water emulsion may contain span 85 and/or lecithin and/or tricaprylin.

Typically for human administration QS21 and 3D-MPL will be present in a vaccine in the range of 1µg - 200µg, such as 10-100µg, preferably 10µg - 50µg per dose.

Typically the oil in water will comprise from 2 to 10% squalene, from 2 to 10% alpha tocopherol and from 0.3 to 3% tween 80. Preferably the ratio of squalene: alpha tocopherol is equal to or less than 1 as this provides a more stable emulsion. Span 85 may also be present at a level of 1%. In some cases it may be advantageous that the vaccines of the present invention will further contain a stabiliser.

Non-toxic oil in water emulsions preferably contain a non-toxic oil, e.g. squalane or squalene, an emulsifier, e.g. Tween 80, in an aqueous carrier. The aqueous carrier may be, for example, phosphate buffered saline.

A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil in water emulsion is described in WO 95/17210.

The present invention also provides a polyvalent vaccine composition comprising a vaccine formulation of the invention in combination with other antigens, in particular antigens useful for treating cancers, autoimmune diseases and related conditions. Such a polyvalent vaccine composition may include a TH-1 inducing adjuvant as hereinbefore described.

While the invention has been described with reference to certain BASB129, BASB130 and BASB131 polypeptides and polynucleotides, it is to be understood that this covers fragments of the naturally occurring polypeptides and polynucleotides, and similar polypeptides and polynucleotides with additions, deletions or substitutions which do not



substantially affect the immunogenic properties of the recombinant polypeptides or polynucleotides.

#### **Compositions, kits and administration**

In a further aspect of the invention there are provided compositions comprising a BASB129, BASB130 and BASB131 polynucleotide and/or a BASB129, BASB130 and BASB131 polypeptide for administration to a cell or to a multicellular organism.

The invention also relates to compositions comprising a polynucleotide and/or a polypeptides discussed herein or their agonists or antagonists. The polypeptides and polynucleotides of the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to an individual. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide and/or polynucleotide of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration. The invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides, polynucleotides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide and/or polynucleotide, such as the soluble form of a polypeptide and/or polynucleotide of the present invention, agonist or antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides, polynucleotides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, solutions, powders and the like.

For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular

individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100  $\mu\text{g/kg}$  of subject.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.

Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

#### **Sequence Databases, Sequences in a Tangible Medium, and Algorithms**

Polynucleotide and polypeptide sequences form a valuable information resource with which to determine their 2- and 3-dimensional structures as well as to identify further sequences of similar homology. These approaches are most easily facilitated by storing the sequence in a computer readable medium and then using the stored data in a known macromolecular

structure program or to search a sequence database using well known searching tools, such as the GCG program package.

Also provided by the invention are methods for the analysis of character sequences or strings, particularly genetic sequences or encoded protein sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and similarity analysis, DNA, RNA and protein structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, codon usage analysis, nucleic acid base trimming, and sequencing chromatogram peak analysis.

A computer based method is provided for performing homology identification. This method comprises the steps of: providing a first polynucleotide sequence comprising the sequence of a polynucleotide of the invention in a computer readable medium; and comparing said first polynucleotide sequence to at least one second polynucleotide or polypeptide sequence to identify homology.

A computer based method is also provided for performing homology identification, said method comprising the steps of: providing a first polypeptide sequence comprising the sequence of a polypeptide of the invention in a computer readable medium; and comparing said first polypeptide sequence to at least one second polynucleotide or polypeptide sequence to identify homology.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

## DEFINITIONS

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case may be, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heine, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs. Computer program methods to determine identity between two sequences include, but are not limited to, the GAP program in the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN (Altschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990), and FASTA( Pearson and Lipman *Proc. Natl. Acad. Sci. USA* 85: 2444-2448 (1988). The BLAST family of programs is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Parameters for polypeptide sequence comparison include the following:

Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)

WO 01/19862

PCT/EP00/09034

Comparison matrix: BLOSSUM62 from Henikoff and Henikoff,  
Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992)

Gap Penalty: 8

Gap Length Penalty: 2

A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Parameters for polynucleotide comparison include the following:

Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the default parameters for nucleic acid comparisons.

A preferred meaning for "identity" for polynucleotides and polypeptides, as the case may be, are provided in (1) and (2) below.

(1) Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to the reference sequence of SEQ ID NO:1, wherein said polynucleotide sequence may be identical to the reference sequence of SEQ ID NO:1 or may include up to a certain integer number of nucleotide alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more

contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \bullet y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in SEQ ID NO:1,  $y$  is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and  $\bullet$  is the symbol for the multiplication operator, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is it may be 100% identical, or it may include up to a certain integer number of nucleic acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one nucleic acid deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleic acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleic acid alterations for a given percent identity is determined by multiplying the total number of nucleic acids in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleic acids in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \bullet y),$$

wherein  $n_n$  is the number of nucleic acid alterations,  $x_n$  is the total number of nucleic acids in SEQ ID NO:1,  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc.,  $\bullet$  is the symbol for the multiplication operator, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ .

(2) Polypeptide embodiments further include an isolated polypeptide comprising a polypeptide having at least a 50,60, 70, 80, 85, 90, 95, 97 or 100% identity to a polypeptide reference sequence of SEQ ID NO:2, wherein said polypeptide sequence may be identical to the reference sequence of SEQ ID NO:2 or may include up to a certain integer number of amino acid alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of amino acid alterations is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \bullet y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2,  $y$  is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and  $\bullet$  is the symbol for



the multiplication operator, and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

By way of example, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is it may be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \bullet y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2,  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and  $\bullet$  is the symbol for the multiplication operator, and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

"Individual(s)," when used herein with reference to an organism, means a multicellular eukaryote, including, but not limited to a metazoan, a mammal, an ovid, a bovid, a simian, a primate, and a human.



WO 01/19862

PCT/EP00/09034

variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Disease(s)" means any disease caused by or related to infection by a bacteria, including, for example, otitis media in infants and children, pneumonia in elderlies, sinusitis, nosocomial infections and invasive diseases, chronic otitis media with hearing loss, fluid accumulation in the middle ear, auditive nerve damage, delayed speech learning, infection of the upper respiratory tract and inflammation of the middle ear.

**EXAMPLES:**

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.

**Example 1: DNA sequencing of the BASB129, BASB130 and BASB131 gene from *Moraxella catarrhalis* strain ATCC 43617.**

The BASB129, BASB130 and BASB131 gene of SEQ ID NO:1, 3 or 5 is from *Moraxella catarrhalis* strain ATCC 43617. The translation of the BASB129, BASB130 and BASB131 polynucleotide sequence is showed in SEQ ID NO:2, 4 or 6.

**Example 2: Construction of Plasmid to Express Recombinant BASB129, BASB130 AND BASB131**

**A: Cloning of BASB129, BASB130 AND BASB131 .**

The *EcoRI* and *SaII* restriction sites engineered into reverse amplification primers, permit directional cloning of a PCR product into the *E.coli* expression plasmid pTLZ2 such that a mature BASB129, BASB130 or BASB131 protein can be expressed as a fusion protein containing a (His)<sub>6</sub> affinity chromatography tag at the C-terminus. The BASB129, BASB130 and BASB131 PCR product is purified from the amplification reaction using silica gel-based spin columns (QiaGen) according to the manufacturers instructions. To produce the required *EcoRI* and *SaII* termini necessary for cloning, purified PCR product is sequentially digested to completion with *EcoRI* and *SaII* restriction enzymes as recommended by the manufacturer (Life Technologies). Following the first restriction digestion, the PCR product is purified via spin column as above to remove salts and eluted in sterile water prior to the second enzyme digestion.

The digested DNA fragment is again purified using silica gel-based spin columns prior to ligation with the pTLZ2 plasmid.

#### B: Production of Expression Vector.

To prepare the expression plasmid pTLZ2 for ligation, it is similarly digested to completion with both *EcoRI* and *SaII* and then treated with calf intestinal phosphatase (CIP, ~0.02 units / pmole of 5' end, Life Technologies) as directed by the manufacturer to prevent self ligation. An approximately 5-fold molar excess of the digested fragment to the prepared vector is used to program the ligation reaction. A standard ~20 µl ligation reaction (~16°C, ~16 hours), using methods well known in the art, is performed using T4 DNA ligase (~2.0 units / reaction, Life Technologies). An aliquot of the ligation (~5 µl) is used to transform electro-competent JM109 cells according to methods well known in the art. Following a ~2-3 hour outgrowth period at 37°C in ~1.0 ml of LB broth, transformed cells are plated on LB agar plates containing ampicillin (100 µg/ml). Antibiotic is included in the selection. Plates are incubated overnight at 37°C for ~16 hours. Individual ApR colonies are picked with sterile toothpicks and used to "patch" inoculate fresh LB ApR plates as well as a ~1.0 ml LB ApR broth culture. Both the patch plates and the broth culture are incubated overnight at 37°C in either a standard incubator (plates) or a shaking water bath. A whole cell-based PCR analysis is employed to verify that transformants contain the BASB129, BASB130 and BASB131 DNA insert. Here, the ~1.0 ml overnight LB Ap broth culture is transferred to a 1.5 ml polypropylene tube and the cells collected by centrifugation in a Beckmann microcentrifuge (~3 min., room temperature, ~12,000 X g). The cell pellet is suspended in ~200µl of sterile water and a ~10µl aliquot used to program a ~50µl final volume PCR reaction containing both BASB129, BASB130 and BASB131 forward and reverse amplification primers. Final concentrations of the PCR reaction components are essentially the same as those specified in example 2 except ~5.0 units of *Taq* polymerase is used. The initial 95°C denaturation step is increased to 3 minutes to ensure thermal disruption of the bacterial cells and liberation of plasmid

DNA. An ABI Model 9700 thermal cycler and a 32 cycle, three-step thermal amplification profile, i.e. 95°C, 45sec; 55-58°C, 45sec, 72°C, 1min., are used to amplify the BASB129, BASB130 AND BASB131 fragment from the lysed transformant samples. Following thermal amplification, a ~20µl aliquot of the reaction is analyzed by agarose gel electrophoresis (0.8 % agarose in a Tris-acetate-EDTA (TAE) buffer). DNA fragments are visualized by UV illumination after gel electrophoresis and ethidium bromide staining. A DNA molecular size standard (1 Kb ladder, Life Technologies) is electrophoresed in parallel with the test samples and is used to estimate the size of the PCR products. Transformants that produced the expected size PCR product are identified as strains containing a BASB129, BASB130 and BASB131 expression construct. Expression plasmid containing strains are then analyzed for the inducible expression of recombinant BASB129, BASB130 and BASB131.

#### C: Expression Analysis of PCR-Positive Transformants.

For each PCR-positive transformant identified above, ~5.0 ml of LB broth containing ampicillin (100 µg/ml) is inoculated with cells from the patch plate and grown overnight at 37 °C with shaking (~250 rpm). An aliquot of the overnight seed culture (~1.0 ml) is inoculated into a 125 ml erlenmeyer flask containing ~25 of LB Ap broth and grown at 37 °C with shaking (~250 rpm) until the culture turbidity reaches O.D.600 of ~0.5, i.e. mid-log phase (usually about 1.5 - 2.0 hours). At this time approximately half of the culture (~12.5 ml) is transferred to a second 125 ml flask and expression of recombinant BASB129, BASB130 and BASB131 protein induced by the addition of IPTG (1.0 M stock prepared in sterile water, Sigma) to a final concentration of 1.0 mM. Incubation of both the IPTG-induced and non-induced cultures continues for an additional ~4 hours at 37 °C with shaking. Samples (~1.0 ml) of both induced and non-induced cultures are removed after the induction period and the cells collected by centrifugation in a microcentrifuge at room temperature for ~3 minutes. Individual cell pellets are suspended in ~50µl of sterile water, then mixed with an equal volume of 2X Laemelli SDS-PAGE sample buffer containing 2-mercaptoethanol, and placed in

boiling water bath for ~3 min to denature protein. Equal volumes (~15µl) of both the crude IPTG-induced and the non-induced cell lysates are loaded onto duplicate 12% Tris/glycine polyacrylamide gel (1 mm thick Mini-gels, Novex). The induced and non-induced lysate samples are electrophoresed together with prestained molecular weight markers (SeeBlue, Novex) under conventional conditions using a standard SDS/Tris/glycine running buffer (BioRad). Following electrophoresis, one gel is stained with commassie brilliant blue R250 (BioRad) and then destained to visualize novel BASB129, BASB130 and BASB131 IPTG-inducible protein(s). The second gel is electroblotted onto a PVDF membrane (0.45 micron pore size, Novex) for ~2 hrs at 4 °C using a BioRad Mini-Protean II blotting apparatus and Towbin's methanol (20 %) transfer buffer. Blocking of the membrane and antibody incubations are performed according to methods well known in the art. A monoclonal anti-RGS (His)<sub>3</sub> antibody, followed by a second rabbit anti-mouse antibody conjugated to HRP (QiaGen), is used to confirm the expression and identity of the BASB129, BASB130 and BASB131 recombinant protein. Visualization of the anti-His antibody reactive pattern is achieved using either an ABT insoluble substrate or using Hyperfilm with the Amersham ECL chemiluminescence system.

### **Example 3: Production of Recombinant BASB129, BASB130 AND BASB131**

#### **Bacterial strain**

A recombinant expression strain of *E. coli* JM109 containing a plasmid (pTLZ2) encoding BASB129, BASB130 or BASB131 from *M. catarrhalis*. is used to produce cell mass for purification of recombinant protein. The expression strain is cultivated on LB agar plates containing 100µg/ml ampicillin ("Ap") to ensure that the pTLZ2 was maintained. For cryopreservation at -80 °C, the strain is propagated in LB broth containing the same concentration of antibiotics then mixed with an equal volume of LB broth containing 30% (w/v) glycerol.

#### **Media**

The fermentation medium used for the production of recombinant protein consists of 2X YT broth (Difco) containing 100µg/ml Ap. Antifoam is added to medium for the fermentor at 0.25 ml/L (Antifoam 204, Sigma). To induce expression of the BASB129, BASB130 or BASB131 recombinant protein, IPTG (Isopropyl β-D-Thiogalactopyranoside) is added to the fermentor (1 mM, final).

#### Fermentation

A 500-ml erlenmeyer seed flask, containing 50ml working volume, is inoculated with 0.3 ml of rapidly thawed frozen culture, or several colonies from a selective agar plate culture, and incubated for approximately 12 hours at  $37 \pm 1^\circ\text{C}$  on a shaking platform at 150rpm (Innova 2100, New Brunswick Scientific). This seed culture is then used to inoculate a 5-L working volume fermentor containing 2X YT broth and both Ap antibiotics. The fermentor (Bioflo 3000, New Brunswick Scientific) is operated at  $37 \pm 1^\circ\text{C}$ , 0.2 - 0.4 VVM air sparge, 250 rpm in Rushton impellers. The pH is not controlled in either the flask seed culture or the fermentor. During fermentation, the pH range is 6.5 to 7.3 in the fermentor. IPTG (1.0 M stock, prepared in sterile water) is added to the fermentor when the culture reaches mid-log of growth ( $\sim 0.7$  O.D.600 units). Cells are induced for 2 - 4 hours then harvested by centrifugation using either a 28RS Heraeus (Sepatech) or RC5C superspeed centrifuge (Sorvall Instruments). Cell paste is stored at -20 C until processed.

#### Example 4: Purification of recombinant BASB129, BASB130 AND BASB131 from

##### *E. coli*

#### Extraction-Purification

Cell paste from IPTG induced culture is resuspended in 60 ml of phosphate buffer pH 7.5 containing 1mM AEBSF and 1mM Aprotinin as protease inhibitors. Cells are lysed in a cell disruptor, centrifuged, washed and re-centrifuged. The pellet is suspended in 100 mM  $\text{NaH}_2\text{PO}_4$ , 10 mM Tris-HCl buffer pH 8 containing 6M Guanidium Chloride (buffer A) and left for 1 hour at room temperature. Total extract is centrifuged at



27,000g for 20 minutes. Supernatant is incubated for 1 hour at room temperature with Ni-NTA superflow resin equilibrated in buffer A. Resin is washed twice with 100 mM NaH<sub>2</sub>PO<sub>4</sub>, 10 mM Tris-HCl buffer pH 6.3, containing 8M Urea (buffer B). Elution is performed successively with buffer B adjusted to pH 5.9 then pH 4.5. Fractions containing BASB121 antigen are neutralized with 25% volume of 0.2M phosphate buffer pH 7.5. Pooled fractions are dialysed successively against 100 mM NaH<sub>2</sub>PO<sub>4</sub> containing 8M Urea, then 4M Urea, then 2M Urea and finally against PBS pH 7.4 containing 0.1% Triton X-100. Purified BASB129, BASB130 and BASB131 antigen is quantified using Micro BCA assay reagent.

#### **Example 5: Production of Antisera to Recombinant BASB129, BASB130 AND BASB131**

Polyvalent antisera directed against the BASB129, BASB130 and BASB131 protein are generated by vaccinating rabbits with the purified recombinant BASB129, BASB130 and BASB131 protein. Animals are bled prior to the first immunization ("pre-bleed") and after the last immunization.

Anti-BASB129, BASB130 and BASB131 protein titres are measured by an ELISA using purified recombinant BASB129, BASB130 and BASB131 protein. The titre is defined as mid-point titers calculated by 4-parameter logistic model using the XL Fit software.

The antisera are also used as the first antibody to identify the protein in a western blot as described in example 7 below. The western-blot is used to demonstrate the presence of anti-BASB129, BASB130 and BASB131 antibody in the sera of immunized animals.

#### **Example 6: Immunological characterization: Surface exposure of BASB129,**

**BASB130 AND BASB131**

Anti-BASB129, BASB130 AND BASB131 protein titres are determined by an ELISA using formalin-killed whole cells of *Moraxella catarrhalis*. The titre is defined as mid-point titers calculated by 4-parameter logistic model using the XL Fit software.

The titre observed with the rabbit or mouse immune sera demonstrates that the BASB129, BASB130 AND BASB131 protein is present at the surface of *M. catarrhalis* cells.

**Example 7. Immunological Characterisation: Western Blot Analysis**

Several strains of *M. catarrhalis* including ATCC 43617, as well as clinical isolates from various geographic regions, are grown on Muller Hinton agar plates for 24 hours at 36°C. Several colonies are used to inoculate broth. Cultures are grown until the A<sub>620</sub> is approximately 0.6 and cells are collected by centrifugation. Cells are then concentrated and solubilized in PAGE sample buffer. The solubilized cells are then resolved on 4-20% polyacrylamide gels and the separated proteins are electrophoretically transferred to PVDF membranes. The PVDF membranes are then pretreated with saturation buffer. All subsequent incubations are carried out using this pretreatment buffer.

PVDF membranes are incubated with preimmune serum or rabbit or mouse immune seru. PVDF membranes are then washed.

PVDF membranes are incubated with biotin-labeled sheep anti-rabbit or mouse Ig. PVDF membranes are then washed 3 times with wash buffer, and incubated with streptavidin-peroxydase. PVDF membranes are then washed 3 times with wash buffer and developed with 4-chloro-1-naphtol.

Detection of a protein corresponding to BASB129, BASB130 and BASB131 expected molecular weight that is reactive with the antisera is used to demonstrate that this protein is produced by and conserved in all *Moraxella* strains tested.

**Example 8: Immunological characterization: Bactericidal Activity**

Complement-mediated cytotoxic activity of anti-BASB129, BASB130 and BASB131 antibodies is examined to determine the vaccine potential of BASB129, BASB130 and BASB131 protein antiserum that is prepared as described above. The activities of the pre-immune serum and the anti-BASB129, BASB130 and BASB131 antiserum in mediating complement killing of *M. catarrhalis* are examined.

Strains of *M. catarrhalis* are grown on plates. Several colonies are added to liquid medium. Cultures are grown and collected until the A620 is approximately 0.4. After one wash step, the pellet is suspended and diluted.

Preimmune sera and the anti-BASB129, BASB130 and BASB131 sera is deposited into the first well of a 96-wells plate and serial dilutions are deposited in the other wells of the same line. Live diluted *M. catarrhalis* is subsequently added and the mixture is incubated. Complement is added into each well at a working dilution defined beforehand in a toxicity assay.

Each test includes a complement control (wells without serum containing active or inactivated complement source), a positive control (wells containing serum with a know titer of bactericidal antibodies), a culture control (wells without serum and complement) and a serum control (wells without complement).

Bactericidal activity of rabbit or mice antiserum (50% killing of homologous strain) is measured.

**Example 9: Presence of Antibody to BASB129, BASB130 AND BASB131 in Human Convalescent Sera**

Western blot analysis of purified recombinant BASB129, BASB130 and BASB131 is performed as described in Example 7 above, except that a pool of human sera from children infected by *M. catarrhalis* is used as the first antibody preparation. This is used to show that antisera from naturally infected individuals react to the purified recombinant protein.

**Example 10: Efficacy of BASB129, BASB130 AND BASB131 vaccine: enhancement of lung clearance of *M. catarrhalis* in mice.**

This mouse model is based on the analysis of the lung invasion by *M. catarrhalis* following a standard intranasal challenge to vaccinated mice.

Groups of mice are immunized with BASB129, BASB130 and BASB131 vaccine. After the booster, the mice are challenged by instillation of bacterial suspension into the nostril under anaesthesia. Mice are killed between 30 minutes and 24 hours after challenge and the lungs are removed aseptically and homogenized individually. The log<sub>10</sub> weighted mean number of CFU/lung is determined by counting the colonies grown on agar plates after plating of dilutions of the homogenate. The arithmetic mean of the log<sub>10</sub> weighted mean number of CFU/lung and the standard deviations are calculated for each group.

Results are analysed statistically.

In this experiment groups of mice are immunized either with BASB129, BASB130 and BASB131 or with a killed whole cells (kwc) preparation of *M. catarrhalis* or sham immunized.

This is used to show that the kwc preparation and the BASB129, BASB130 and BASB131 vaccine induce significant lung clearance as compared to the control group.

**Example 11: Inhibition of *M. catarrhalis* adhesion onto cells by anti-BASB129, BASB130 AND BASB131 antiserum.**

This assay measures the capacity of anti BASB129, BASB130 AND BASB131 sera to inhibit the adhesion of *Moraxella* bacteria to epithelial cells. This activity could prevent colonization of f.i. the nasopharynx by *Moraxella*.

One volume of bacteria is incubated on ice with one volume of pre-immune or anti-BASB129, BASB130 and BASB131 immune serum dilution. This mixture is subsequently added in the wells of a 24 well plate containing a confluent cells culture that is washed once with culture medium to remove traces of antibiotic. The plate is centrifuged and incubated.

Each well is then gently washed. After the last wash, sodium glycocholate is added to the wells. After incubation, the cell layer is scraped and homogenised. Dilutions of the homogenate are plated on agar plates and incubated. The number of colonies on each plate is counted and the number of bacteria present in each well calculated.

This is used to show that bacteria incubated with anti-BASB129, BASB130 and BASB131 antiserum are inhibited in their adherence capacity to the Hep-2 cells.

**Deposited materials**

A deposit containing a *Moraxella catarrhalis* Catlin strain has been deposited with the American Type Culture Collection (herein "ATCC") on June 21, 1997 and assigned deposit number 43617. The deposit was described as *Branhamella catarrhalis* (Frosch and Kolle) and is a freeze-dried, 1.5-2.9 kb insert library constructed from *M. catarrhalis* isolate obtained from a transtracheal aspirate of a coal miner with chronic bronchitis. The deposit is described in Antimicrob. Agents Chemother. 21: 506-508 (1982).

The *Moraxella catarrhalis* strain deposit is referred to herein as "the deposited strain" or as "the DNA of the deposited strain."

The deposited strain contains a full length BASB129, BASB130 and BASB131 gene.

A deposit of the vector pMC-D15 consisting of *Moraxella catarrhalis* DNA inserted in pQE30 has been deposited with the American Type Culture Collection (ATCC) on February 12 1999 and assigned deposit number 207105.

The sequence of the polynucleotides contained in the deposited strain / clone, as well as the amino acid sequence of any polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.

The deposit of the deposited strains have been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The deposited strains will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposited strains are provided merely as convenience to those of skill in the art and are not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. §112.

Applicant's or agent's file reference number FB/BM45414	International Application No. <b>PCT/EP 00 / 09034</b>
---	--

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 65 lines 1-28.	
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet <input type="checkbox"/>
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country) 10801 UNIVERSITY BLVD, MANASSAS, VIRGINIA 20110-2209, UNITED STATES OF AMERICA	
Date of deposit 21 June 1997 and 12 February 1999	Accession Number 43617 and 207105
C. ADDITIONAL INDICATIONS (leave blank if not applicable)	This information is continued on an additional sheet <input type="checkbox"/>
In respect of those designations where a European Patent is sought, a sample of the deposited microorganisms will be made available until the publication of the mention of the grant of the European Patent or until the date on which the application has been refused or withdrawn, only by issue of such a sample to an expert nominated by the person requesting the sample.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input type="checkbox"/>	This sheet was received with the international application
Authorized officer	

For International Bureau use only	
<input type="checkbox"/>	This sheet was received by the International Bureau on:
Authorized officer	

**SEQUENCE INFORMATION****BASB129, BASB130 and BASB131 Polynucleotide and Polypeptide Sequences****SEQ ID NO:1*****Moraxella catarrhalis* BASB129 polynucleotide sequence from strain ATCC43617**

ATGAAAGCACAAATTTACAACCCATAAAGTCATCGGCGGACTATTTGTAGGTGGCATGATGCTAAATGCACATGCAGCACC  
TGAATTATATGGTTACGCAAATCTTGTCGTTTCTGCTAATCATAAAAAACAACCAACAAGACAACCAATGTCAGTACAT  
CAACAACAGACCGCCCTATCTGTATAGCAGCGGATCAGCATTGGCCCTAGAGGGTCTGAAAAGTTAAATGATGATTAT  
GAGGTTTTGTACAAGTTGGAGTACCGTCTAGAAAATGATGGTGATTTACGCAATGAAAAATCAAGCAGCCAGATGGTAC  
TGAAAAGACTGTTGCTAAAACACGCAATTTTGAGGCTCGTGATTCATGGATTGGCGTGAAGCATAAAAAGTATGGTACCA  
TCAAGCGGGTCTGATGTTGTCTTTGGATCCATATGTGCGTTATACTGCCTATTGGCGTCAGGCGTAGATGGGGTGCCT  
ACCAATAATACCATTGCATACGAATCACCAAAAATCAAAGATGTTAGTTTTCAGGCGATGTACATCTTAGATGAAAATAA  
AGAGACAGATACCATTGATCGTGATGGTTATTCATTGCTTGCTCAAGAAAAACACAGATACATATAATGTTGGTGCAGCTT  
ATGCCATTTTGGTAAAGCAAAAACCTCTTATGGCAAGATTAACATACTGCGCGTGTGACAGGTAATTATAAAATTAAT  
GAGGATTATAAAGTAGGTGGTATCTATCAGCATGTCGGCTATGCCAATGACGACAGTGCCAAAAATAATACAGAAACAAGC  
TGTTGGCGTGGCTTTCGACGATTTTAAAGACAAATGGACTCATACCGCACACATGAATCTTGTGAATAATCCTAGTGGGA  
AAAAGGGCGATGGGTTTGAGCTGATCGGAGCAATTGACCGTGATTTCTAAAAATGTCTCTGCAGGCATGGATATCACC  
TATGGTAACTTTAACTACGCAACAGAAAAAGAACTTTACATCAACCCAACATCTATGCGACTGTATATTTTAA

**SEQ ID NO:2*****Moraxella catarrhalis* BASB129 polypeptide sequence deduced from the polynucleotide of SEQ ID NO:1**

MKAQFTTLKVIIGGLFVGGMMLNHAAPELYGYANLVVSANHKKTNTKNTNVSTSTDRPYLYSSGSRIGLRGSEKLNDDYE  
VLYKLEYRLENDGDLRNEKIKQPDGTEKTVAKTRNFEARDSWIGVKKHKYGTIKAGRMLSLDPYVRYTAYLASGVDGVRTN  
NTIAYESPKIKDVSFQAMYILDENKETDTIDRDGYSLLVKKNTDYNVGAAYYFGKAKTSYGKINYTARVTGNKYINEDY  
KVGGIYQHVGYANDDSAKNNTQAVGVALQHFQDKWTHAHMNLVNNPSGKKGDFELIGAIDRDISKNVSAGMDITYGNF  
NYATEKESYINPTIYATVYF

**SEQ ID NO:3*****Moraxella catarrhalis* BASB130 polynucleotide sequence from strain ATCC43617**

ATGCGTTTTATACCTTTTGCTGTAACCTTTTTATCTTTTACTGGCTCCTCCATCTTTCTGTGGCCAAAGCTCAGATTGC  
ACCAGACCCAAACCAAGCAAATCTTTCTGCAATAACCGATGATCGTCGTCAGGCGGCTCTTGACATTTAGCAAGACAAG  
ATTTGGCAGCAACAGATGACGACATGGGTGTCGATATCAATCAAACCAATATCAACCAGCCAAATTGGCAAGATGACAAG  
AATGGCGATTTCATGTTTTTGGTTGATGAGATTGACTTTGTGATTGAGGGTGGAGAAGATAAACATATTCTAGGTATGAC  
GCCGAGCAATTTACGCAGCTTGCTATCGCCCTGTTGGACCGGACAAAGCCAAACATATGCTCTTAATCACTGCATCAACA  
ATCACAACCTATCTTTAATTGTAGATATTGCCCATGAATTAAGCGTGGTTATTTAACTAGCAGTATTAGCATT  
GAAGAGCAGGATTTATCACTAAAAAATCACTTTAACAGTCCATGCTGGCAAGGTGAAAAAGGTGATATTGGCCGATGC  
TAGCAAAACGCCAACTTATGTCAAAGCCGCCATTCTCTTAAGTTCAATCAAGCCTTTTCGTCTGCATATTTAGAAACAAG  
GTCTAGATAATTTAAACGCATCGATCCAACGGCAACCGTGCAGATTATACCAAGCAGCTCCAGTAATGTCGCCAATGAT  
ATTGACATTAAACACCACAAACCTTGGTTTTAGTGATTTACTCATTAGGATGGACCGCAGTCAAAGCGCTGATTTTGGCAT  
TAATATTGATAACAGTTTATCCAAAGATTATGGCAATTATCTGATTTCTGCTAATGTTTCGTGCTAACAACCTCATGCATC  
TTAACGATGAATGGAATCTTTCTGCCAACTATCCATTGGCGCGCTGATTGACGCTGCCCAAAATGATCTTGGGGTTCAG  
GTGGGCAAGGATAGGCAGGTTAATTATCAGCCTTCCTTGACTATTCTTATGGATTGTATAAATTTCTGCCACACACAG  
CCACCACCAATACCAGCAATTTCTGAAGGGCTTCATGCGCCCTTGACTTATCATGGCACCAGCAAGACAAGCTCAATTG



WO 01/19862

PCT/EP00/09034

GATTGTCTCGTTTATTGCACCGTGATGGCAATCAAAAGACTGAAGGTTATATAAAGGTTAATCACAACGAAGCAGTAAT  
TATATTGATGATGTTAATCTTGAAGTGCAAAACCGCCGCACACAGGATATAACATTGGCATCACTCATCAGCATCATCT  
TCACCAAGGTGGTTATTTGTATGCCAACTTGGATTATAAGCAAGGAACAGGGGCACTAAAAGCAAAGCCTGCACCTGAAG  
AGCATATTTATGATGCTTTTGGGCGACAACCTACCCAGTGAGGGTTTTGCAAAAGCACCATTGTTGCTACTATACACCAGT  
TTCCAAAAGCCATTTGTGTTAAACAACCCAAATGATACTGAACAAGCGCAAGATAAAGCAACAGCAAATAAACCCATTTA  
CACATCCATTCCTCTCACTTATACTGCTAGATTACAAGCCCAATATGCCAAACAACCTCCTGTACCATCTGATTATTCT  
ATTTGGGTGGCAGATATAGCATTAAAGGCATTAAAGAGGGAAATTATTTATCAGGAGAACATGGCTTTAGCCTATCCCAA  
GAACCTGCTTGGCAATTGCCATTACAGAATCTTAATCAGCACTTTAGTACAAATGCAACAGCGCCAGTTGTATGCAAG  
TATTGATCAAGGCTATGCTTATGGAAGAAACACTCTTAATAATCAACGCCATATCTTGGCTGGAGCGGTTGTTATGAGGT  
ATTATTTTCAAGGCAGTCAAGATCCAAGAATTCAAGAAACACAAAATGGCTTGACTCATTTCAAAGAATCAAATACTTAT  
CTAAATAACACACCAACACAGCTCATTGGATATATTCATTGGAAAAGGAATTAAGACGCCTGAATTTATGAAGAAAGA  
AACCGTCGTGGGTGTGAGTGCCAGCATTGAGTTTAA

#### SEQ ID NO:4

*Moraxella catarrhalis* BASB130 polypeptide sequence deduced from the polynucleotide of  
SEQ ID NO:3

MRFI PFAVTL LLSFTGSSI FSVAKAQIAPDPTKANLSAITDDRRQAALAHLARQDLAATDDDMGV DINQTNINQPNWQDDKN  
GDSCFLVDEIDFVIEGGEDKHILGMTPSNRLSLLSPLLDRTKPTYALNHCINNHNLSLIVDIAHNELLKRGYLTSSISIEE  
QDLSTKKLTLTVHAGKVKKVILADASKTPTYVKAAPLKFNAFRLSYLEQGLDNLKRIDPTATVQIIPSSSSNVANDIDI  
NTTNLGFSDLLIRMDRSQSASVFGINIDNSLSKDYGNYLISANVRANLMLHNDENWLSANYPLARLIDAAQNLDLGVQVGKD  
RQVNYHASLTIPTGYLYKFSATHSHHQYQQFLEGLHAPLTYHGTSKTSISIGLSRLLHRDGNQKTEGYIKVNHKRSSNYIDDV  
NLEVQNRRTTGYNIGITHQHHLHQGGYLYANLDYKQGTGALKAKPAPEEHIYDAFGRQLPSEGFAPAKIWSLYTSFQKPFV  
LNNPNDTEQAQDKATANKPIYTSIPLTYTARLQAQYAKQLPVPSDLFYLGGRYSIKGIKEGNYLSGEHGFSLSQELAWQLP  
LQNLNQHFSTNANSALYASIDQGYAYGKNTLNNQRHILAGAVGMRYFQGSQDPRIQETQNLTHFKESNTYLNNTPTTA  
HLDIFIGKGIKTPEFMKKETVVGVSASIEF

#### SEQ ID NO:5

*Moraxella catarrhalis* BASB131 polynucleotide sequence from strain ATCC43617

ATGAAAATGCCCTATTTTTTGTCTTTGGGATTATTGTTAGTACAGCAGGCTGATGCTGATTATAGCTTGCTTGATGCCCA  
AAAACAGCTCATGAGCAGCAGCCCTGCCATCCAAGCAAGTCATGCCTTGATCAAGCTGATGTCTTACAAGCAGAATCAT  
TACAAAAATTACACTATCCTAGGATATCGCTCAATGCACACGCCCTTTGTACTGCAACAAAACAGCAGCATACCCCTTAGAT  
CATATCAAAGAGCAGACCGCCAGCACATTAACACCCATTTTGACCATCGCTTTGGCAGTGCCCGCGATGGTCTGTTGGA  
TGCTTTGCACAACAGCACCCAAACCGCCCTTGACCGCTGCGCTGACCATCAAGATGTCAAGTTACGCCATGATGGCATT  
CCCCAAACATTACCGCCACGATACCCATCTATACAGGTGGCTTAATCAGCAGCACCAAAAATATCGCCAATCTACAAGCA  
CAGCGTGGTAAATTTGGATTACAAGAAGCATCTCTTTGGCAAACTTAATTTGATTGCGCATTTATTTAATGTGCAATT  
ACAAAAGCAGCTGACCGACACACAAACAAACATGCTTAGTGCCATGCAGTTACATGTAGATAATGCTTATAAATTAGAAC  
AGCAAGGTTTTATCAGTCGTGGACAGCGTATGCAATTTGAAGTGGCAGCAATCAGGTACAAAGACTGTATCAAAGCACC  
CAAAATCAGCACCAAAACAGCATTTATGAACCTTGCTGTTTTGCTTGTTTGGCCACATTGAACCGCTAAGCACACCGCT  
GTTTATCAACACCCAGCATCGCCCCAATTGGCAAGCATTACTCAAAGACTCCCAAAATACACCATTAAATCAAAGCTAA  
AAACCGACATTTTGCTTGCCGATGAAAATATCGCCCTAAGACAATCCACCAAAAAACCAAAATTGCCGCTGTGGCTCGT  
TATACCTTAGATGATAAGCCTGATTGGTTTGCAGGTGTGGCGGTTCTTACAACCTATTCTTGGGCATTGACCGTGATAA  
GCAGATTGGGGCAGCACACCTACAAAAACAAGCAGCCCAATTGGGTCATGAACAAGTCAATGAACACATCACAAACCA  
TGCACACCGCTTATGGCGAGATGGTGTGTCACAAAAAACCCACGCCCTACTACAACAAAATCGTCAAGCCGCCAAAGAA  
AATTGGCGTATCGACAGCTGTCTTTTCAAGAAGGTTTGGGACGGTGGCAGGTGTGGTTGATGCCCAAAGTGCTTTATC  
ACAGATTGACAGCGAAACCGCTCTAAATGCGTATCGCTACCTTTTGGCACTGGCGACGCTGTTGCATTACACAGGGACAA  
TTGATGACTTTGATGATTATTTGCTTTGGATGATGCTCATAAACTGTGA



**CLAIMS:**

1. An isolated polypeptide comprising an amino acid sequence which has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6, over the entire length of SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6 respectively.
2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6, over the entire length of SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6 respectively.
3. The polypeptide as claimed in claim 1 comprising the amino acid sequence selected from the group consisting of: SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6.
4. An isolated polypeptide of SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6.
5. An immunogenic fragment of the polypeptide as claimed in any one of claims 1 to 4 in which the immunogenic activity of said immunogenic fragment is substantially the same as the polypeptide of SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6.
6. A polypeptide as claimed in any of claims 1 to 5 wherein said polypeptide is part of a larger fusion protein.
7. An isolated polynucleotide encoding a polypeptide as claimed in any of claims 1 to 6.
8. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 85% identity to the amino acid sequence of SEQ ID NO:2; SEQ ID NO:4

or SEQ ID NO:6 over the entire length of SEQ ID NO:2; SEQ ID NO:4 or SEQ ID NO:6 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.

9. An isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2; SEQ ID NO:4 or SEQ ID NO:6 over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.

10. An isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to that of SEQ ID NO:1, 3 or 5 over the entire length of SEQ ID NO:1, 3 or 5 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.

11. The isolated polynucleotide as claimed in any one of claims 7 to 10 in which the identity is at least 95% to SEQ ID NO:1,3 or 5.

12. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2; SEQ ID NO:4 or SEQ ID NO:6.

13. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1; SEQ ID NO:3 or SEQ ID NO:5.

14. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2; SEQ ID NO:4 or SEQ ID NO:6 obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1; SEQ ID NO:3 or SEQ ID NO:5 or a fragment thereof.

15. An expression vector or a recombinant live microorganism comprising an isolated polynucleotide according to any one of claims 7 - 14.

16. A host cell comprising the expression vector of claim 15 or a subcellular fraction or a membrane of said host cell expressing an isolated polypeptide comprising an amino acid sequence that has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6.

17. A process for producing a polypeptide of claims 1 to 6 comprising culturing a host cell of claim 16 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

18. A process for expressing a polynucleotide of any one of claims 7 – 14 comprising transforming a host cell with the expression vector comprising at least one of said polynucleotides and culturing said host cell under conditions sufficient for expression of any one of said polynucleotides.

19. A vaccine composition comprising an effective amount of the polypeptide of any one of claims 1 to 6 and a pharmaceutically acceptable carrier.

20. A vaccine composition comprising an effective amount of the polynucleotide of any one of claims 7 to 14 and a pharmaceutically effective carrier.

21. The vaccine composition according to either one of claims 19 or 20 wherein said composition comprises at least one other *Moraxella catarrhalis* antigen.

22. An antibody immunospecific for the polypeptide or immunological fragment as claimed in any one of claims 1 to 6.

23. A method of diagnosing a *Moraxella catarrhalis* infection, comprising identifying a polypeptide as claimed in any one of claims 1 - 6, or an antibody that is immunospecific

for said polypeptide, present within a biological sample from an animal suspected of having such an infection.

24. Use of a composition comprising an immunologically effective amount of a polypeptide as claimed in any one of claims 1 – 6 in the preparation of a medicament for use in generating an immune response in an animal.

25. Use of a composition comprising an immunologically effective amount of a polynucleotide as claimed in any one of claims 7 - 14 in the preparation of a medicament for use in generating an immune response in an animal.

26. A therapeutic composition useful in treating humans with *Moraxella catarrhalis* disease comprising at least one antibody directed against the polypeptide of claims 1 – 6 and a suitable pharmaceutical carrier.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number  
WO 01/19862 A3

- (51) International Patent Classification<sup>7</sup>: C07K 14/22, 16/12, C12N 1/21, 15/31, A61K 38/16, 39/40, G01N 33/569
- (74) Agent: PRIVETT, Kathryn Louise; SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).
- (21) International Application Number: PCT/EP00/09034
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date:  
14 September 2000 (14.09.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (30) Priority Data:  
9921694.7 14 September 1999 (14.09.1999) GB  
9921693.9 14 September 1999 (14.09.1999) GB  
9922829.8 25 September 1999 (25.09.1999) GB
- (71) Applicant (*for all designated States except US*): SMITHKLINE BEECHAM BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): THONNARD, Joelle [BE/BE]; SmithKline Beecham Biologicals s.a., Rue de L'Institut 89, B-1330 Rixensart (BE).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
4 October 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/19862 A3

(54) Title: POLYPEPTIDES FROM MORAXELLA (BRANHAMELLA) CATARRHALIS

(57) Abstract: The invention provides BASB129, BASB130 and BASB131 polypeptides and polynucleotides encoding BASB129, BASB130 and BASB131 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

Docket No.: BM45414

PCT/EP00/09034

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

***POLYPEPTIDES FROM MORAXELLA (BRANHAMELLA) CATARRHALIS***

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 14 September 2000 as Serial No. PCT/EP00/09034  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9921694.7	Great Britain	14 September 1999	Yes
9921693.9	Great Britain	14 September 1999	Yes
9922829.8	Great Britain	25 September 1999	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number    Filing Date





## SEQUENCE LISTING

&lt;110&gt; SmithKline Beecham Biologicals S.A.

&lt;120&gt; Novel Compounds

&lt;130&gt; BM45414

&lt;160&gt; 6

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;211&gt; 1035

&lt;212&gt; DNA

<213> *Moraxella catarrhalis*

&lt;400&gt; 1

```

atgaaagcac aatttacaac cctaaaagtc atcggcggac tatttgtagg tggcatgatg      60
ctaaatgcac atgcagcacc tgaattatat ggttacgcaa atcttgctcgt ttctgctaata 120
cataaaaaaa caaccaacaa gacaaccaat gtcagtacat caacaacaga ccgccccctat 180
ctgtatagca gcggatcacg cattggcctt agagggtctg aaaagttaaa tgatgattat 240
gaggttttgt acaagtgtga gtaccgtcta gaaaatgatg gtgatttacg caatgaaaaa 300
atcaagcagc cagatggtac tgaaaagact gttgctaaaa cacgcaattt tgaggctcgt 360
gattcatgga ttggcgtgaa gcataaaaag tatggtacca tcaaggcggg tcgtatggtg 420
tctttggatc catatgtgcy ttatactgcc tatttggcgt caggcgtaga tggggtgcgt 480
accaataata ccattgcata cgaatcacca aaaaacaaa atgttagttt tcaggcgatg 540
tacatcttag atgaaaataa agagacagat accattgatc gtgatggtta ttcattgctt 600
gtcaagaaaa acacagatac atataatgtt ggtgcagctt atgcctattt tggtaaagca 660
aaaacctctt atggcaagat taactatact gcgcgtgtga caggtaatta taaaattaat 720
gaggattata aagtaggtgg tatctatcag catgtcggct atgccaatga cgacagtgcc 780
aaaaataata cagaacaagc tgttggcgtg gctttgcagc attttaaaga caaatggact 840
cataccgcac acatgaatct tgtgaataat cctagtggga aaaagggcga tgggtttgag 900
ctgatcggag caattgaccg tgatatttct aaaaatgtct ctgcaggcat ggatatcacc 960
tatggttaact ttaactacgc aacagaaaaa gaatcttaca tcaacccaac tatctatgcy 1020
actgtatatatt tttaa                                     1035

```

&lt;210&gt; 2

&lt;211&gt; 344

&lt;212&gt; PRT

<213> *Moraxella catarrhalis*

&lt;400&gt; 2

```

Met Lys Ala Gln Phe Thr Thr Leu Lys Val Ile Gly Gly Leu Phe Val
 1           5           10           15
Gly Gly Met Met Leu Asn Ala His Ala Pro Glu Leu Tyr Gly Tyr
 20           25           30
Ala Asn Leu Val Val Ser Ala Asn His Lys Lys Thr Thr Asn Lys Thr
 35           40           45
Thr Asn Val Ser Thr Ser Thr Thr Asp Arg Pro Tyr Leu Tyr Ser Ser
 50           55           60
Gly Ser Arg Ile Gly Leu Arg Gly Ser Glu Lys Leu Asn Asp Asp Tyr
 65           70           75           80
Glu Val Leu Tyr Lys Leu Glu Tyr Arg Leu Glu Asn Asp Gly Asp Leu

```

85 90 95  
 Arg Asn Glu Lys Ile Lys Gln Pro Asp Gly Thr Glu Lys Thr Val Ala  
 100 105 110  
 Lys Thr Arg Asn Phe Glu Ala Arg Asp Ser Trp Ile Gly Val Lys His  
 115 120 125  
 Lys Lys Tyr Gly Thr Ile Lys Ala Gly Arg Met Leu Ser Leu Asp Pro  
 130 135 140  
 Tyr Val Arg Tyr Thr Ala Tyr Leu Ala Ser Gly Val Asp Gly Val Arg  
 145 150 155 160  
 Thr Asn Asn Thr Ile Ala Tyr Glu Ser Pro Lys Ile Lys Asp Val Ser  
 165 170 175  
 Phe Gln Ala Met Tyr Ile Leu Asp Glu Asn Lys Glu Thr Asp Thr Ile  
 180 185 190  
 Asp Arg Asp Gly Tyr Ser Leu Leu Val Lys Lys Asn Thr Asp Thr Tyr  
 195 200 205  
 Asn Val Gly Ala Ala Tyr Ala Tyr Phe Gly Lys Ala Lys Thr Ser Tyr  
 210 215 220  
 Gly Lys Ile Asn Tyr Thr Ala Arg Val Thr Gly Asn Tyr Lys Ile Asn  
 225 230 235 240  
 Glu Asp Tyr Lys Val Gly Gly Ile Tyr Gln His Val Gly Tyr Ala Asn  
 245 250 255  
 Asp Asp Ser Ala Lys Asn Asn Thr Glu Gln Ala Val Gly Val Ala Leu  
 260 265 270  
 Gln His Phe Lys Asp Lys Trp Thr His Thr Ala His Met Asn Leu Val  
 275 280 285  
 Asn Asn Pro Ser Gly Lys Lys Gly Asp Gly Phe Glu Leu Ile Gly Ala  
 290 295 300  
 Ile Asp Arg Asp Ile Ser Lys Asn Val Ser Ala Gly Met Asp Ile Thr  
 305 310 315 320  
 Tyr Gly Asn Phe Asn Tyr Ala Thr Glu Lys Glu Ser Tyr Ile Asn Pro  
 325 330 335  
 Thr Ile Tyr Ala Thr Val Tyr Phe  
 340

<210> 3  
 <211> 2037  
 <212> DNA  
 <213> *Moraxella catarrhalis*

<400> 3  
 atgcggtttta taccttttgc tgtaactctt ttatctttta ctggctcctc catcttttct 60  
 gtggccaaag ctcagattgc accagaccca accaaagcaa atcttttctgc aataaccgat 120  
 gatcgtcgctc aggcggctct tgcacattta gcaagacaag atttggcagc aacagatgac 180  
 gacatgggtg tcgatatcaa tcaaaccaat atcaaccagc caaattggca agatgacaag 240  
 aatggcgatt catgtttttt ggttgatgag attgactttg tgattgaggg tggagaagat 300  
 aaacatattc taggtatgac gccgagcaat ttacgcagct tgctatcgcc cctgttggac 360  
 cggacaaaagc caacatatgc tcttaatcac tgcataca atcacaacct atctttaatt 420  
 gtagatatatg ccataatga attactaaag cgtgggttatt taactagcag tattagcatt 480  
 gaagagcagg atttatcaac taaaaaactc actttaacag tccatgctgg caaggtgaaa 540  
 aaggtgatat tggccgatgc tagcaaaacg ccaacttatg tcaaagccgc cattcctctt 600  
 aagttcaatc aagccttttc tctgtcatat ttagaacaag gtctagataa tttaaaacgc 660  
 atcgatccaa cggcaaccgt gcagattata ccaagcagct ccagtaatgt cgccaatgat 720  
 attgacatta acaccacaaa ccttggtttt agtgatttac tcattaggat ggaccgcagt 780  
 caaagcgtctg tatttggcat taatattgat aacagtttat ccaaagatta tggcaattat 840  
 ctgattttctg ctaatgttgc tgctaacaac ctcatgcac ttaacgatga atggaatctt 900  
 tctgccaact atccattggc gcgcctgatt gacgctgccc aaaatgatct tggggttcag 960





<210> 5  
 <211> 1410  
 <212> DNA  
 <213> *Moraxella catarrhalis*

<400> 5  
 atgaaaatgc cctatttttt gcttttggga ttattggttag tacagcaggc tgatgctgat 60  
 tatagcttgc ttgatgccca aaaacagctc atgagcagca gccctgccat ccaagcaagt 120  
 catgccttgt atcaagctga tgtcttacaa gcagaatcat tacaaaaatt acactatcct 180  
 aggatatcgc tcaatgcaca cgcctttgta ctgcaacaaa acagcagcat acccttagat 240  
 catatcaaag agcagaccgc ccagcacatt aacacccatt ttgaccatcg ctttggcagt 300  
 gcccccgatg gtctgttgga tgctttgcac aacagcacc aaaccgccct tgaccgccctg 360  
 cctgaccatc aagatgtcaa gttacgccat gatggcatta ccccaaacat taccgccacg 420  
 ataccatctc atacaggtgg cttaatcagc agcaccaaaa atatcgccaa tctacaagca 480  
 cagcgtggta aatttggatt acaagaacgc atctctttgg caaaacttaa tttgattcgc 540  
 cattattttta atgtgcaatt acaaaagcag ctgaccgaca cacaacaaaa catgcttagt 600  
 gccatgcagt tacatgtaga taatgcttat aaattagaac agcaagggtt tatcagtcgt 660  
 ggacagcgta tgcaatttga agtggcacgc aatcaggtac aaagactgta tcaaagcacc 720  
 caaaatcagc accaaaacag catttatgaa cttgtgtgtt tgcttggttt gccccacatt 780  
 gaaccgctaa gcacaccgct gtttatcaac acccagcatc gcccgaattg gcaagcatta 840  
 ctcaaagact cccaaaatac accattaaat caaaagctaa aaaccgacat tttgcttgcc 900  
 gatgaaaata tcgccctaag acaatccacc aaaaaaccaa aaattgccgc tgtggctcgt 960  
 tataccttag atgataagcc tgattgggtt gcagggtgtg cggtttctta caacctattc 1020  
 ttgggcattg accgtgataa gcagattggg gcagcacacc tacaaaaaca agcagcccaa 1080  
 ttgggtcatg aacaagtcaa tgaacacatc acaaccacca tgcacaccgc ttatggcgag 1140  
 atgggtgctg cacaacaaac ccacgcccta ctacaacaaa atcgtcaagc cgccaaagaa 1200  
 aatttgcgta tccagacgct gtcttttcaa gaagggtttg ggacgggtggc aggtgtgggt 1260  
 gatgcccata gtgctttatc acagattgac agcgaaaccg ctctaaatgc gtatcgctac 1320  
 cttttggcac tggcgacgct gttgcattac acagggacaa ttgatgactt tgatgattat 1380  
 ttgtctttgg atgatgctca taaactgtga 1410

<210> 6  
 <211> 469  
 <212> PRT  
 <213> *Moraxella catarrhalis*

<400> 6  
 Met Lys Met Pro Tyr Phe Leu Leu Leu Gly Leu Leu Leu Val Gln Gln  
 1 5 10 15  
 Ala Asp Ala Asp Tyr Ser Leu Leu Asp Ala Gln Lys Gln Leu Met Ser  
 20 25 30  
 Ser Ser Pro Ala Ile Gln Ala Ser His Ala Leu Tyr Gln Ala Asp Val  
 35 40 45  
 Leu Gln Ala Glu Ser Leu Gln Lys Leu His Tyr Pro Arg Ile Ser Leu  
 50 55 60  
 Asn Ala His Ala Phe Val Leu Gln Gln Asn Ser Ser Ile Pro Leu Asp  
 65 70 75 80  
 His Ile Lys Glu Gln Thr Ala Gln His Ile Asn Thr His Phe Asp His  
 85 90 95  
 Arg Phe Gly Ser Ala Pro Asp Gly Leu Leu Asp Ala Leu His Asn Ser  
 100 105 110  
 Thr Gln Thr Ala Leu Asp Arg Leu Pro Asp His Gln Asp Val Lys Leu  
 115 120 125  
 Arg His Asp Gly Ile Thr Pro Asn Ile Thr Ala Thr Ile Pro Ile Tyr  
 130 135 140  
 Thr Gly Gly Leu Ile Ser Thr Lys Asn Ile Ala Asn Leu Gln Ala  
 145 150 155 160  
 Gln Arg Gly Lys Phe Gly Leu Gln Glu Arg Ile Ser Leu Ala Lys Leu

